

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

APpropriateness of percutaneous Coronary interventions in patients with ischemic HEart disease in Italy: The APACHE Pilot study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016909
Article Type:	Research
Date Submitted by the Author:	20-Mar-2017
Complete List of Authors:	Leonardi, Sergio; Fondazione IRCCS Policlinico San Matteo, Marino, Marcello; Aziende Socio Sanitarie Territoriale di Crema Crimi , Gabriel ; Fondazione IRCCS Policlinico San Matteo, Maiorana, Florinda; Fondazione IRCCS Policlinico San Matteo Rizzotti, Diego; Fondazione IRCCS Policlinico San Matteo Lettieri, Corrado; Azienda Socio Sanitaria Territoriale di Mantova Bettari, Luca; Azienda Socio Sanitaria Territoriale di Cremona Zuccari, Marco Sganzerla, Paolo; Agenzia di Tutela della Salute di Bergamo Ovest Tresoldi, Simone ; Azienda Ospedaliera di Desio e Vimercate Adamo, Marianna; Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Ghiringhelli, Sergio; Ospedale di Circolo e Fondazione Macchi Sponzilli, Carlo; Ospedale San Paolo Pasquetto, Giampaolo; Presidio Ospedaliero di Monselice Pavei, Andrea; Presidio di Conegliano Pediton, Luigi; Presidio Ospedaliero di Cittadella Bassan, Luciano; Azienda ULSS 4 Alto Vicentino Bollati, Mario; IRCCS Policlinico San Donato Camisasca, Paola; Azienda Ospedaliera San Gerardo Trabattoni, Daniela; Centro Cardiologico Monzino Brancati, Marta; Fondazione Poliambulanza Istituto Ospedaliero Poli, Arnaldo; Aziende Socio Sanitarie Territoriale Ovest Milanese Panciroli, Claudio Lettino, Maddalena; Istituto Clinico Humanitas Tarelli, Giuseppe; Istituto Clinico Humanitas Tarantini, Giuseppe; Azienda Ospedaliera di Padova De Luca, Leonardo; Ospedale di Tivoli Varbella, Ferdinando; 1Cardiology Unit, Ospedale degli Infermi, Musumeci, Giuseppe; Azienda Ospedaliera S Croce e Carle Cuneo De Servi, Stefano; IRCCS Sesto San Giovanni
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Health services research
Keywords:	Coronary heart disease < CARDIOLOGY, Percutaneous Coronary Intervention, Multidisciplinary Decision Making

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For peer review only

Appropriateness of percutaneous Coronary interventions in patients with ischemic HEart disease in Italy: The APACHE Pilot study

Sergio Leonardi, MD, MHS, FESC¹ Marcello Marino, MD² Gabriele Crimi, MD¹ Florinda Maiorana, MSc,¹ Diego Rizzotti, MSc¹ Corrado Lettieri, MD³ Luca Bettari, MD⁴ Marco Zuccari, MD⁵ Paolo Sganzerla, MD⁶ Simone Tresoldi, MD⁷ Marianna Adamo, MD⁸ Sergio Ghiringhelli, MD⁹ Carlo Sponzilli, MD¹⁰ Giampaolo Pasquetto, MD¹¹ Andrea Pavei, MD¹² Luigi Pedon, MD¹³ Luciano Bassan, MD¹⁴ Mario Bollati, MD¹⁵ Paola Camisasca, MD¹⁶ Daniela Trabattoni, MD¹⁷ Marta Brancati, MD¹⁸ Arnaldo Poli, MD¹⁹ Claudio Panciroli, MD²⁰ Maddalena Lettino, MD²¹ Giuseppe Tarelli²¹, MD Giuseppe Tarantini, MD²² Leonardo De Luca, MD²³ Ferdinando Varbella, MD²⁴, Giuseppe Musumeci, MD²⁵ and Stefano De Servi, MD²⁶.

- 1: Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 2: Ospedale Maggiore di Crema, Crema, Italy
- 3: ASST Mantova – Ospedale Carlo Poma, Mantova, Italy
- 4: ASST Cremona – Ospedale di Cremona, Cremona, Italy
- 5: Ospedale Fornaroli di Magenta, Magenta, Italy
- 6: ASST Bergamo ovest – Ospedale di Treviglio, Italy
- 7: Azienda Ospedaliera di Desio e Vimercate, Vimercate, Italy
- 8: Spedali Civili di Brescia, Brescia, Italy
- 9: Ospedale di Circolo Fondazione Macchi, Varese, Italy
- 10: Ospedale San Paolo, Milano, Italy
- 11: Ospedali Riuniti Padova Sud Madre Teresa di Calcutta, Monselice, Italy
- 12: Presidio Ospedaliero di Conegliano, Conegliano, Italy
- 13: Presidio Ospedaliero di Cittadella, Cittadella, Italy
- 14: ULSS 4 Alto Vicentino, Thiene, Italy
- 15: IRCCS Policlinico San Donato, San Donato Milanese, Italy
- 16: Ospedale San Gerardo, Monza, Italy
- 17: Centro Cardiologico Monzino, Milano, Italy
- 18: Fondazione Poliambulanza, Brescia, Italy
- 19: ASST Ovest Milanese, Legnano, Italy
- 20: ASST di Lodi, Lodi, Italy
- 21: Humanitas Research Hospital, Rozzano (MI), Italy
- 22: Ospedale di Padova, Padova, Italy
- 23: Ospedale San Giovanni Evangelista, Tivoli (Rome), Italy
- 24: Ospedale degli Infermi, Rivoli, Italy
- 25: ASST – Papa Giovanni XXIII- Bergamo, Italy
- 26: IRCCS MultiMedica, Milano, Italy

Word Count: 4093

Address for correspondence

Sergio Leonardi, MD, MHS, FESC
Fondazione IRCCS Policlinico S. Matteo
Viale Golgi 19
27100
Pavia, Italy
S.Leonardi@smatteo.pv.it

Abstract *Word count: 305*

Objectives: To first explore in Italy appropriateness of indication, adherence to guideline recommendations, and mode of selection for coronary revascularization.

Design: Retrospective, pilot study.

Setting: Twenty-two percutaneous coronary intervention (PCI)-performing hospitals (20 patients/site), 13 (59%) with on-site cardiac surgery.

Participants: 440 patients who received PCI for stable coronary artery disease (CAD) or non-ST elevation acute coronary syndrome were independently selected in a 4:1 ratio with half diabetics.

Primary and Secondary Outcome Measures: Proportion of patients who received appropriate PCI using validated appropriate use scores (ie AUS ≥ 7). Also, in patients with stable CAD, we examined adherence to the following ESC recommendations: a) % of patients with complex coronary anatomy treated after heart-team discussion; b) % of fractional flow reserve-guided PCI for borderline stenoses in patients without documented ischemia; c) % of patients receiving guideline-directed medical therapy at the time of PCI as well as use of provocative test of ischemia according to pre-test probability (PTP) of CAD.

Results: Of the 401 mappable PCIs (91%), 38.7% were classified as appropriate, 47.6% as uncertain, and 13.7% as inappropriate. Median PTP in stable CAD patients without known coronary anatomy was 69% (78% intermediate PTP, 22% high PTP). Their use was similar ($p=0.71$) in patients with intermediate ($n=140$, 63%) and with high PTP ($n=40$, 66%). In patients with stable CAD ($n=352$) guideline adherence to the 3 recommendations explored was: a) 11%; b) 25%; c) 23%. AUS was higher in patients evaluated by the heart team as compared to patients who were not [7 (6,8) vs 5 (4,7); $P=0.001$].

Conclusions: Use of heart-teams approaches and adherence to guideline recommendations on coronary revascularization in a real world setting is limited. This pilot study documents the feasibility of measuring appropriateness and guideline adherence in clinical practice and identifies substantial opportunities for quality improvement.

Study Registration: NCT02748603.

Strengths and Limitations of this study

- APACHE is a first-in-class study in Italy designed to measure the degree of appropriateness of indication, multi-disciplinary decision-making processes, and implementation of key guideline recommendations in patients undergoing PCI.
- This study, with patients with stable CAD and diabetes, was intentionally designed to focus on high-risk patients for inappropriate PCI. Also, it examined the appropriateness of PCI indication, not of coronary angiography. Therefore we have no data to inform appropriateness of surgical revascularization, nor indication to invasive angiography.
- Rather than an epidemiological study, APACHE intention was to serve as first initiative sponsored by a national medical society to measure care process and improve quality. By quality we intend the degree of match between health care services and the needs they are intended to meet.²⁰ APACHE was designed to first quantify this match, inform the design of future investigations on this topic, and promote a continuous review of practice that may, in turn, inform a more effective, efficient, and equitable resources allocation, and ultimately, better outcomes for patients.

Introduction

Percutaneous coronary intervention (PCI) has dramatically improved the prognosis of patients with coronary artery disease (CAD). Yet, many patients receive PCI whose clinical indication appears uncertain or inappropriate, especially in the non-acute setting.^{1,2} The development of appropriate use criteria by cardiovascular societies has provided the basis for a standardized approach to systematically assess the clinical appropriateness of PCI³ and has produced a reduction of the volume of non-acute PCI as well as an increase in the proportion of procedures classified as appropriate⁴ but these studies have been mostly performed in the US.

In Europe, data on appropriateness of indication and mode of selection for coronary revascularization strategies as well as the degree of implementation of guideline recommendations are lacking. European Society of Cardiology (ESC) guidelines^{5,6} urge the implementation of a multidisciplinary decision-making approach – the heart team – to select the optimal mode of revascularization but data on the implementation of this process in patients with complex coronary artery disease (CAD), including those with stable CAD and diabetes, are scarce. Specifically the ESC^{5,6} recommend that 1) complex pathologies in stable patients, including lesions of the left main or proximal left anterior descending artery (LAD) and three-vessel disease, should in general not be treated *ad hoc*, but discussed by the heart team; 2) pressure derived fractional flow reserve (FFR) should be used to identify haemodynamically relevant coronary lesion(s) in stable patients when evidence of ischaemia is not available; and 3) patients with stable CAD must receive guideline-recommended medical treatment prior to revascularization.

We designed the APpropriAteness of percutaneous Coronary interventions in patients with ischemic HEart disease – APACHE Pilot study to first explore the degree of appropriateness of indication of PCI, multi-disciplinary decision-making

1
2
3 processes, and implementation of key guideline recommendations in patients
4
5 undergoing PCI in Italy.
6
7

8 9 **Methods**

10 11 **Study Design and Patient Selection**

12 APACHE was designed as a pilot initiative to assess appropriateness of PCI
13
14 indication and adherence to key guideline recommendations on coronary
15
16 revascularization in patients with predominantly stable CAD and diabetes, considered
17
18 to be at high risk for inappropriate indication and mode for coronary revascularization
19
20 (ie PCI treatment in patients with an indication for CABG). All PCI performing
21
22 hospitals of the Lombardia and Veneto region in Italy, serving a population of \approx
23
24 15.000.000 people, were invited to participate in the study. Twenty-two sites agreed
25
26 to participate, obtained regulatory approval, and were eventually included.
27
28

29
30 At each participating hospital, 20 patients were independently selected on-site
31
32 by the study team (see online appendix) among consecutive patients who were
33
34 admitted in the previous year for an elective procedure to treat stable CAD or urgently
35
36 for an episode of non-ST elevation acute coronary syndrome in a 4:1 ratio and
37
38 without site personnel involvement in the selection of the cases identified to minimize
39
40 selection bias. The study population was also selected to preserve an overall 1:1 ratio
41
42 on diabetes status. If the number of patients selected was insufficient older cases were
43
44 evaluated for possible inclusion. Due to the low likelihood of receiving a *redo*
45
46 procedure as well as the inability to measure a SYNTAX score, patients with a history
47
48 of bypass surgery were excluded.
49
50
51
52

53 54 **Data Collection, Core Angiographic Assessment, and Central Heart Team**

55 Variables of interest were collected by the study team during dedicated visits
56
57 at participating hospitals via clinical chart abstraction. Sites were requested to provide
58
59
60

1
2
3 the complete clinical chart, including the coronary angiogram of the index PCI.
4
5 Source documentation was reviewed in full to abstract symptoms status (angina
6
7 class); cardiovascular risk factors and comorbidities; medical therapy at time of PCI;
8
9 site-reported indication for PCI; presence, results, and timing of any noninvasive
10
11 functional test, fractional flow reserve (FFR) or intracoronary imaging, if performed;
12
13 coronary anatomy and reported significance of angiographic stenosis for treated
14
15 lesion(s) on the catheterization report; and evidence for heart-team discussion
16
17 involving a cardiac surgeon. Finally, pretest probability (PTP) of significant coronary
18
19 artery disease was calculated in patients with stable CAD according to guideline
20
21 recommendations ⁶.
22
23
24

25 The Angiographic Core Laboratory (ACL) was composed by two independent
26
27 physicians with experience in interventional cardiology (MM, GC) who centrally and
28
29 independently reviewed coronary angiography for each patient to define 1) baseline
30
31 SYNTAX score 2) category of coronary anatomy (eg. one, two or three-vessel CAD
32
33 with or without proximal LAD involvement) ³ and 3) presence of “borderline”
34
35 angiographic stenosis (50% to 60%). For the SYNTAX score a disagreement was
36
37 arbitrarily considered to be present if there was a between score difference ≥ 10 or
38
39 both scores were not in the same tertile (0-22, 23-32, >32). In case of agreement an
40
41 average SYNTAX score was calculated. In case of disagreement between reviewers
42
43 the case was first resolved by consensus. If a consensus could not be reached (or if the
44
45 case was deemed particularly challenging) the conflict was resolved by the central
46
47 heart team. Anatomical category and presence of borderline coronary stenoses were
48
49 analyzed by a single reviewer (GC or MM).
50
51
52
53

54 The central heart team was represented by four members – two interventional
55
56 cardiologists (LDL, FV), one cardiac surgeon (GT), and one clinical cardiologist
57
58
59
60

(ML) – nominated by the Italian Society of Interventional Cardiology (SICI-GISE) among recognized experts in their respective specialty. The role of the central heart team was to review cases with unresolved conflicts by the ACL, cases considered complex or challenging by the study team or cases with incomplete or conflicting documentation. Assessments of the central heart team were performed by consensus.

Evaluation of Appropriateness of Indications for Coronary Revascularization

The comprehensive documentation of indications for PCI was formally examined based on the 2013 ACC/AHA/SCAI/AMA-PCPI/NCQA Percutaneous Coronary Intervention Measurement Set.⁷ This diagnostic measure was defined as the proportion of patients whose clinical documentation includes, at a minimum, the following elements:

1. Priority (acute coronary syndrome, elective, urgent, emergency/salvage); 2. Presence and severity of angina symptoms (eg, Canadian Cardiovascular Society classification system); 3. Use of antianginal medical therapies within 2 weeks before the procedure, if any; 4. Presence, results, and timing of noninvasive stress test, FFR, or intravascular ultrasound, if performed; and 5. Significance of angiographic stenosis on coronary angiography for treated lesion.

Appropriateness of indication of coronary revascularization was examined by assigning to each procedure an appropriate use score (AUS), with a score of 1 indicating a completely inappropriate procedure to a score of 9 indicating a completely appropriate one.³ Scores of 7 to 9 indicate that revascularization is considered generally appropriate and likely to improve patients' symptoms or survival. Scores of 1 to 3 considered generally inappropriate while scores of 4 to 6 indicate a clinical scenario for which the likelihood that coronary revascularization will improve health outcomes or symptoms is uncertain. This score was defined by

1
2
3 considering clinical presentation; severity of angina; extent of ischemia on
4
5 noninvasive testing; presence of other prognostic factors, such as congestive heart
6
7 failure or depressed left ventricular function; extent of medical therapy at the time of
8
9 PCI; and extent of anatomic coronary disease. If the scenario was not considered by
10
11 the consensus document,³ the procedure was considered non mappable.
12
13

14 To limit site operator-related bias, the study team calculated two scores for
15
16 each procedure:
17

- 18 1. AUS_{SITE}, based on site-reported extent of anatomic coronary disease;
- 19 2. AUS_{CORE}, based on ACL reported extent of anatomic coronary disease.
20
21
22

23 Evaluation of adherence to ESC Guidelines and Heart Team Processes

24 In patients with stable CAD we assessed adherence to three class I recommendations
25
26 according to ESC guidelines^{5,6}:
27
28

29 **Recommendation 1:** Proportion of patients with stable CAD and complex anatomy
30
31 (including lesions of the left main, proximal left anterior descending (LAD) and/or
32
33 three-vessel CAD) who were treated after local heart team discussion. This
34
35 recommendation was explored using both site-reported and ACL-reported coronary
36
37 anatomy. We also explored adherence to this recommendation by calculating the
38
39 proportion of patients with complex anatomy who received *ad hoc* PCI without
40
41 documented heart team discussion. To better define optimal mode of coronary
42
43 revascularization, the SYNTAX II score⁸ as well as the Society of Thoracic Surgeons
44
45 (STS)⁹, and EuroScore II¹⁰ were calculated.
46
47
48
49

50 **Recommendation 2:** Proportion of patients with stable CAD, no evidence of
51
52 ischemia, and borderline lesions according to the ACL in whom FFR was used to
53
54 identify haemodynamically relevant coronary lesion(s).
55

56 Specifically, this recommendation was explored as follows:
57
58
59
60

- a) Proportion of patients with no functional test (ie test negative or not performed) and at least one borderline stenosis according to ACL in whom pressure-derived FFR was used;
- b) Proportion of patients with no functional test or asymptomatic and at least one borderline stenosis according to ACL in whom pressure derived FFR was used;
- c) Proportion of patients with no functional test or asymptomatic and site-reported multivessel CAD in whom pressure derived FFR was used. ¹¹

Recommendation 3: Proportion of patients with stable CAD who received guideline-directed medical therapy prior to revascularization. ⁶

Specifically:

- a) Proportion of patients without known allergy or documented intolerance taking low dose aspirin (75-150 mg daily) or clopidogrel;
- b) Proportion of patients without known allergy or documented intolerance receiving a statin;
- c) Proportion of patients with heart failure, hypertension or diabetes treated with an ACE-inhibitor or angiotensin receptor blocker;
- d) Proportion of patients on optimal medical therapy defined as drugs for event prevention (aspirin and/or clopidogrel; a statin; an ACE-I/ARB if heart failure, hypertension or diabetes) plus at least one drug for angina relief if symptomatic, such as beta-blockers, calcium channel blockers, long acting nitrates, ivabradine, or ranolazine.

In patients with NSTEMI/ACS, we examined the proportion of PCI procedures performed within 24 hours of admission in patients with a Global Registry of Acute Coronary Events (GRACE) score > 140.

1
2
3 Finally we assessed, by structured investigators surveys, the presence of
4 written institutional protocols developed locally by the Heart Team in accordance
5 with current guidelines including specific anatomical criteria and clinical subsets that
6 may be (or should not be) treated *ad hoc* as well as the modalities and timing for
7 convocation of heart team meetings.
8
9
10
11
12

13 14 15 **Statistical Analysis and Sample Size Considerations**

16 Categorical data are presented as counts and proportion and continuous data as
17 median (25th, 75th percentile) and were analyzed, as appropriate, using Pearson's X^2
18 (or Fisher's exact) and Wilcoxon rank-sum test. Given the lack of prior studies to
19 estimate appropriateness of coronary revascularization in Italy, sample size estimation
20 was challenging. The study was powered on the primary subgroup of interest, patients
21 with stable CAD, assuming an appropriateness of 35% in this patient population
22 based on prior reports.⁴ Using a normal approximation to the binomial distribution for
23 this proportion a population of 350 stable CAD patients was needed to obtain a 95%
24 confidence interval between 30% and 40% for appropriateness.¹² The study obtained
25 institutional review board approval by all participating hospitals and is registered on
26 ClinicalTrials.gov ID: NCT02748603.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Sponsor and Funding**

44 The APACHE study was designed by the chair and principal investigator and
45 approved by the institutional review board at each participating center. The study was
46 sponsored by the Italian Society of Invasive Cardiology (SICI-GISE), a nonprofit
47 organization, and received unrestricted grant support from the Abbott Vascular and
48 Daiichi-Sankyo. The sponsor and funders had no role in the design of the study, the
49 collection, monitoring, analysis, and interpretation of the data, or the writing of the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 report. The first draft of the manuscript was written by the first author. All the authors
4
5 vouch for the accuracy and completeness of the data and all analyses.
6
7

8 9 **Results**

10 Of the 22 hospitals included, 13 (59%) have onsite cardiac surgery and 4
11 (18%) are private hospitals. Overall, PCI procedures of 440 patients (performed
12 between January 2014 and May 2016) were included: 352 for patients with stable
13 CAD and 88 with NSTEMI [12 with unstable angina and 76 with non-ST elevation
14 myocardial infarction; median GRACE score 109 (89.5, 125.5), median Can Rapid
15 risk stratification of Unstable angina patients Suppress ADverse outcomes with Early
16 implementation of the ACC/AHA guidelines (CRUSADE) score 24 (16,40)]. A
17 SYNTAX score could be calculated in 422 patients (96%) with 87 disagreements
18 (21%) between ACL reviewers. Of these, 55 were resolved by consensus and 32 by
19 the central heart team. Clinical profile of the selected patients stratified by clinical
20 indication is showed in **Table 1**. By design, \approx half of the patients had diabetes
21 (n=216, 49.1%) with a high proportion of patients with dyslipidemia (54%), prior PCI
22 (40%) and history of angina (69%). **Table 2** presents data on indication and test
23 selection in patients with stable CAD. Median PTP of CAD in stable CAD patients
24 without known coronary anatomy was 69% (78% intermediate PTP, 22% high PTP,
25 no patient with low PTP). The use of provocative tests of ischemia was similar
26 (p=0.71) in patients with intermediate (n=140, 63%) and with high PTP (n=40, 66%).
27
28 Of the 88 patients with NSTEMI, a GRACE score > 140 was present in 11 (12%)
29 patients. Of these, 5 patients had PCI within 24 hours.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 53 **Comprehensive Documentation and Appropriateness of Indications for** 54 **Coronary Revascularization** 55 56 57 58 59 60

1
2
3 A comprehensive documentation of PCI indication was present in 427 (97%) patients.
4
5 Most common reasons for unfulfilling this diagnostic measure were the lack of
6
7 documentation in the clinical chart of any non-invasive testing, both functional and
8
9 imaging (n=5) or missing information on therapy at admission (n=8).
10

11
12 An AUS_{SITE} could be calculated in 405 (92%) of patients while the remaining
13
14 35 patients did not have comprehensive documentation of indications for PCI or the
15
16 scenario was not applicable (ie non mappable AUC). The median AUS_{SITE} was 6 (5,7)
17
18 corresponding to 153 (37.8%) of PCI classified as appropriate, 193 (47.7%) as
19
20 uncertain, and 59 (14.6%) as inappropriate AUC, similar in patients with a and
21
22 without diabetes (**Figure 1**). AUS_{SITE} was higher in patients evaluated by the local
23
24 heart team as compared to patients who were not [7 (5,8) vs 5 (4,7); p=0.003].
25
26

27
28 An AUS_{CORE} could be calculated in 401 patients (91%). Of these, 23 (6%)
29
30 required a review by the central heart team. Median AUS_{CORE} was 6 (5,7) with 155
31
32 (38.7%) of PCI classified as appropriate, 191 (47.6%) as uncertain, and 55 (13.7%) as
33
34 inappropriate AUC. AUS_{CORE} results in key subgroups are reported in the
35
36 **Supplementary Figure**. AUS_{CORE} was higher in patients with NSTEMI as
37
38 compared to patients with stable CAD with no significant difference according to
39
40 diabetic status or type of hospitals. AUS_{CORE} was higher in patients evaluated by the
41
42 local heart team as compared to patients who were not [7 (6,8) vs 5 (4,7); p=0.001]
43
44 (**Figure 2**).
45
46
47
48
49
50

51 **Recommendation 1: Proportion of stable CAD patients with complex** 52 **pathologies who were treated after heart team discussion**

53 Of the 352 patients with stable CAD, 148 (42%) had a complex site-reported
54
55 coronary anatomy including significant lesions of the left main (n=16), proximal LAD
56
57 (n=73) and three-vessel disease (n=59). Of these, 17 (11%) underwent local heart
58
59
60

1
2
3 team discussion. Median operative mortality was low-to-intermediate as estimated by
4 both the Euroscore II [1.15 % (0.64, 2.05)] and the STS score [0.92% (0.45,1.81)].
5
6 Also, 118 of the 148 patients with complex site-reported coronary anatomy (80%)
7 received *ad hoc* PCI without evidence of discussion with the local heart team in the
8 clinical chart, with no difference in patients treated at hospitals with or without on-site
9 cardiac surgery (p=0.74). The proportion of patients with complex coronary lesions
10 according to the ACL was 46% (n=164). Of these, 20 (12%) underwent local heart
11 team discussion and 124 (75%) were treated *ad hoc* without evidence of heart team
12 discussion.
13
14
15
16
17
18
19
20
21

22
23 The median SYNTAX score in patients with stable CAD was 12 (8-20), with
24 83% of patients with a score < 23, 13% between 23 and 32, and 4% above 32.
25
26

27 A SYNTAX II score could be calculated in 337 cases (96%). Of these, CABG
28 was the recommended option for 40 patients (12%), PCI the recommended option for
29 14 (4%), and either mode of revascularization was recommended in the remaining
30 283 cases (84%). Of the 40 patients where SYNTAX II score recommended CABG a
31 local heart team discussion was performed in 3 cases (7%). Finally, a total of 75
32 stable CAD patients (21%) with diabetes and multi-vessel CAD underwent *ad hoc*
33 PCI without local heart discussion documented in the patient's chart.
34
35
36
37
38
39
40
41
42

43
44 **Recommendation 2: Proportion of stable CAD patients with no evidence of**
45 **ischemia where pressure derived fractional flow reserve (FFR) was used to**
46 **identify haemodynamically relevant coronary lesion(s).**
47

48
49 Of the 352 patients with stable CAD, 151 (43%) had no objective evidence of
50 ischemia (135 patients had no provocative test of ischemia, 8 had negative testing and
51 8 inconclusive testing), 36 (10%) were asymptomatic and 82 (23%) had multi-vessel
52 CAD according to the site. A pressure-derived FFR to guide PCI was used for 29
53
54
55
56
57
58
59
60

1
2
3 patients (8.2%) with stable CAD while intravascular ultrasound for 12 patients (3%).
4
5 No PCI were guided by coronary optical coherence tomography.
6

7
8 Of the 151 patients with no evidence of ischemia, the ACL identified 28
9
10 patients (18%) with at least one borderline coronary lesion treated with PCI with FFR
11
12 performed in 7 of these 28 cases (25%).
13

14
15 Of the 175 (50%) patients who had no objective evidence of ischemia or were
16
17 asymptomatic, 33 borderline lesions were identified by the ACL with FFR performed
18
19 in 10 cases. In the subgroup of 91 patients who also had site-reported multi-vessel
20
21 CAD, 13 borderline lesions were identified by the ACL, with FFR performed in 4
22
23 cases.
24

25 26 **Recommendation 3: Use of guideline-directed medical therapy at the time of** 27 **PCI in patients with stable CAD** 28

29
30 Of the 352 patients with stable CAD, 299 (85%) were treated with single
31
32 antiplatelet therapy at the time of angiography (292 low-dose aspirin and 7 with
33
34 clopidogrel) and 20 (6%) received dual antiplatelet therapy with aspirin and
35
36 clopidogrel (only 1 reported case of aspirin intolerance who successfully underwent
37
38 aspirin desensitization); 266 (76%) were on a statin (no reported case of statin
39
40 intolerance); 202 (57%) received an ACE-I or an angiotensin receptor blocker (no
41
42 reported case of allergy or intolerance). Among the subgroup of stable CAD patients
43
44 with hypertension, heart failure (or asymptomatic left ventricular ejection fraction of
45
46 40% or less), or diabetes (N=265; 75% of the overall stable CAD population), a
47
48 treatment with ACE-I or ARB was given to 176 patients (66%). Finally, a therapy
49
50 with an anti-anginal agent (beta-blocker, calcium channel blocker, nitrates,
51
52 ivabradine, or ranolazine) was administered to 237 patients overall and to 169 patients
53
54
55
56
57
58
59
60

1
2
3 of the 248 with symptoms of angina (68%). Overall a total of 100 patients (23%)
4
5 received guideline-directed medical therapy at time of PCI.
6
7

8 **Adoption of institutional heart-team protocols**

9
10 Investigators from all participating centers (n=22) were interviewed and all
11
12 responded. A written institutional heart-team protocol was available in 5 (23%)
13
14 centers (1 with on-site cardiac surgery, 4 without on-site cardiac surgery) while in
15
16 other 5 centers (3 with on-site cardiac surgery) heart team meetings were being
17
18 scheduled on a regular basis (usually weekly). All other hospitals (n=12) did not have
19
20 either a heart team institutional protocol or regularly planned heart team meetings.
21
22

23 **Discussion**

24
25 In this pilot investigation we assessed appropriateness of indication of
26
27 coronary revascularization and adherence to key guideline recommendations in a real
28
29 world population with a high prevalence of stable CAD and diabetes as well as
30
31 multidisciplinary decision-making processes. We identified important gaps in
32
33 implementations of guideline recommendations and opportunities to improve the care
34
35 patients undergoing PCI.
36
37
38
39

40 **Considerations on Appropriateness of Indication for Coronary** 41 **Revascularization**

42
43 The proportion of appropriate indication for coronary revascularization was
44
45 39% in the overall population and 32% in patients with stable CAD with similar rates
46
47 observed using local vs ACL anatomical category. These proportions are similar to
48
49 what was observed in the US when AUC were first released in 2009.^{4,13} As expected,
50
51 appropriateness was higher in patients with NSTEMI as compared to patients with
52
53 stable CAD but similar according to diabetes status as well as in hospitals with and
54
55 without on-site cardiac surgery. Importantly both AUC_{SITE} and AUC_{CORE} were
56
57
58
59
60

1
2
3 significantly higher in patients who were evaluated by a heart team suggesting multi-
4
5 disciplinary decision-making is a surrogate of optimal revascularization choice.
6

7
8 In patients with stable CAD a functional testing strategy (used in 62% of
9
10 patients) was far more common than an anatomical-testing strategy with coronary
11
12 CTA (used only for 8% of patients), in agreement with the neutral findings of the
13
14 Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE)
15
16 trial.¹⁴ Notably, the use of functional testing was similar in patients with intermediate
17
18 and with high PTP of significant CAD suggesting that the determination of PTP,
19
20 considered the first major step in clinical decision making in this patient population,⁶
21
22 has limited influence in the real world to define a diagnostic strategy. Also, 33% of
23
24 stable CAD patients with unknown coronary anatomy had neither functional nor
25
26 anatomical testing before PCI and only 38% had maximal anti-ischemic medical
27
28 therapy before PCI, proportions that have contributed to the observed suboptimal
29
30 appropriateness and call for implementation of quality improvements initiatives.
31
32 Indeed, it has been observed that most (55.5%) of Medicare patients with stable CAD
33
34 do not have documentation of ischemia by noninvasive testing prior to elective PCI
35
36 and that pre-PCI stress testing was associated with lower mortality in patients
37
38 undergoing elective PCI.^{15,16} Overall these findings suggest a need to focus on PTP
39
40 assessment in decision-making, appropriate classification of risk by non-invasive
41
42 tests, and optimization of medical therapy before PCI.
43
44
45
46
47

48 **Adherence to and Implementation of ESC Guidelines**

49

50 To explore potential “specialty bias” – ie PCI treatment in patients with an
51
52 indication for CABG – we examined the proportion of patients with complex
53
54 coronary lesions, including significant disease of the left main, proximal LAD, and/or
55
56 three-vessel disease, who were treated *ad hoc* without evidence of heart team
57
58
59
60

1
2
3 discussion in the medical charts. We observed that only \approx one of ten eligible patients
4
5 underwent heart discussion and 75 to 80% of patients with complex coronary
6
7 anatomy were treated *ad hoc*, with no significant differences in sites with and without
8
9 on-site cardiac surgery. To further explore this, we surveyed investigators to better
10
11 understand local decision-making processes. We observed that most sites did not have
12
13 a written institutional protocol and decision of heart team convocation was left at the
14
15 discretion of the interventional cardiologist on call. The high proportion of *ad hoc*
16
17 PCI in patients with complex disease together with the lack of structured local heart
18
19 teams identify a substantial opportunity to improve multidisciplinary decision making
20
21 processes and indicate the need for standardized institutional protocols, that 1) should
22
23 avoid the need for the systematic case-by-case review of all diagnostic angiograms
24
25 but guide the management of complex cases 2) define standards for heart team
26
27 composition and roles, and 3) generate consensus on practical ways to implement
28
29 them.
30
31
32
33

34 The SYNTAX score is also considered by the guidelines to inform choice on
35
36 optimal type of revascularization. This score, which relies on subjective assessment of
37
38 lesions using coronary angiography, is well known to have limited reproducibility.¹⁷
39
40 The highest kappa value observed in a study of the SYNTAX investigators to assess
41
42 intra-observer variability was 0.54, and only 0.36 for bifurcations¹⁷ and inter-
43
44 observer reproducibility was even lower.¹⁸ We therefore decided to adopt a
45
46 conservative approach to define a disagreement between reviewers (arbitrarily defined
47
48 as a difference of at least 10 points or change of tertile) but still observed a
49
50 disagreement in 21% of patients. This variability suggests that for clinical decision-
51
52 making SYNTAX score should not be used in isolation but rather integrated with
53
54 clinical data. The SYNTAX II score was developed to address this need. By
55
56
57
58
59
60

1
2
3 implementing this score in the APACHE population, we observed that in the vast
4 majority of patients (84%) either modality of revascularization was recommended.
5
6
7 However in the 40 patients (12%) where CABG was modality of choice, a heart team
8 discussion was performed only in 3 cases.
9

10
11 Fractional flow reserve, the current gold standard for the functional
12 assessment of lesion severity¹⁹, is recommended (class I, level of evidence A) to
13 identify haemodynamically relevant coronary lesions in stable patients when evidence
14 of ischaemia is not available or to assess the functional consequences of moderate
15 coronary stenoses.⁵ According to the ACL, the proportion of patients without
16 documented ischemia or borderline coronary stenoses who had a FFR guided PCI was
17 25% although the absolute numbers were small (7 FFR in 28 patients). While recent
18 data suggest that FFR use is increasing, these data indicate another gap in use of a
19 well-established technique to define physiological consequences of a coronary
20 stenosis thus optimizing appropriate indication for revascularization.
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Finally, we observed that prescription of guideline-directed medical therapy
35 before PCI was suboptimal with just 23% of patients on “optimal medical therapy”
36 and a high prescription only for antiplatelet therapy before PCI (>90%). This gap may
37 have multiple reasons including resource availability, patient’s compliance, and
38 physician preference but should be an important, and easily modifiable target, for any
39 quality improvement initiative.
40
41
42
43
44
45
46
47

48 Conclusions

49 Use of heart teams approaches and adherence to guideline recommendation on
50 coronary revascularization in a real world setting is limited. The APACHE study
51 identifies substantial opportunities to improve the care of patients undergoing PCI.
52
53
54
55
56
57
58
59
60

Acknowledgments

We thank all investigators and patients who participated in this study to pioneer advancements in clinical care.

References

1. Chan PS, Rao SV, Bhatt DL, Rumsfeld JS, Gurm HS, Nallamothu BK, Cavender MA, Kennedy KF, Spertus JA. Patient and hospital characteristics associated with inappropriate percutaneous coronary interventions. *J Am Coll Cardiol* 2013;62(24):2274-81.
2. Baig SS, Altman DG, Taggart DP. Major geographical variations in elective coronary revascularization by stents or surgery in England. *Eur J Cardiothorac Surg* 2014.
3. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/ SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol* 2012;59(9): 857-81.
4. Desai NR, Bradley SM, Parzynski CS, Nallamothu BK, Chan PS, Spertus JA, Patel MR, Ader J, Soufer A, Krumholz HM, Curtis JP. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. *JAMA* 2015;314(19):2045-53.
5. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;35(37):2541-619.
6. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ,

- Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirim A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013 Oct;34(38):2949-3003.
7. Nallamothu BK, Tommaso CL, Anderson HV, Anderson JL, Cleveland JC Jr, Dudley RA, Duffy PL, Faxon DP, Gurm HS, Hamilton LA, Jensen NC, Josephson RA, Malenka DJ, Maniu CV, McCabe KW, Mortimer JD, Patel MR, Persell SD, Rumsfeld JS, Shunk KA, Smith SC Jr, Stanko SJ, Watts B. ACC/AHA/SCAI/AMA-Convended PCPI/NCQA 2013 performance measures for adults undergoing percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convended Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance. *J Am Coll Cardiol* 2014;63(7):722-45.
 8. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, Colombo A, Holmes DR Jr, Mack M, Feldman T, Morice MC, Stähle E, Onuma Y, Morel MA, Garcia-Garcia HM, van Es GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. *Lancet* 2013;381(9867):639-50.
 9. Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP; Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. *Ann Thorac Surg* 2009;88(1 Suppl):S2-22.
 10. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockowandt U. EuroSCORE II. *Eur J Cardiothorac Surg* 2012;41(4):734-44; discussion 744-5.
 11. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engström T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med*. 2009 Jan 15;360(3):213-24.
 12. Hulley SB, Cummings SR, Browner WS, Grady D, Newman TB. *Designing clinical research : an epidemiologic approach*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. Appendix 6E, page 81.
 13. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA; American College of Cardiology Foundation Appropriateness Criteria Task Force.; Society for Cardiovascular Angiography and Interventions.; Society of

1
2
3 Thoracic Surgeons.; American Association for Thoracic Surgery.; American
4 Heart Association, and the American Society of Nuclear Cardiology Endorsed
5 by the American Society of Echocardiography.; Heart Failure Society of
6 America.; Society of Cardiovascular Computed Tomography.
7 ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for
8 Coronary Revascularization: a report by the American College of Cardiology
9 Foundation Appropriateness Criteria Task Force, Society for Cardiovascular
10 Angiography and Interventions, Society of Thoracic Surgeons, American
11 Association for Thoracic Surgery, American Heart Association, and the
12 American Society of Nuclear Cardiology Endorsed by the American Society
13 of Echocardiography, the Heart Failure Society of America, and the Society of
14 Cardiovascular Computed Tomography. *J Am Coll Cardiol.* 2009 Feb
15 10;53(6):530-53

- 16
17
18 14. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B,
19 Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff
20 MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS,
21 Lee KL; PROMISE Investigators. Outcomes of anatomical versus functional
22 testing for coronary artery disease. *N Engl J Med.* 2015 Apr 2;372(14):1291-
23 300.
- 24 15. Lin GA, Dudley RA, Lucas FL, Malenka DJ, Vittinghoff E, Redberg RF.
25 Frequency of stress testing to document ischemia prior to elective
26 percutaneous coronary intervention. *JAMA* 2008;300(15):1765-73.
- 27 16. Lin GA, Lucas FL, Malenka DJ, Skinner J, Redberg RF. Mortality in
28 Medicare patients undergoing elective percutaneous coronary intervention
29 with or without antecedent stress testing. *Circ Cardiovasc Qual Outcomes.*
30 2013 May 1;6(3):309-14.
- 31 17. Garg S, Girasis C, Sarno G, Goedhart D, Morel MA, Garcia-Garcia HM,
32 Bressers M, van Es GA, Serruys PW; SYNTAX trial investigators. The
33 SYNTAX score revisited: a reassessment of the SYNTAX score
34 reproducibility. *Catheter Cardiovasc Interv.* 2010 May 1;75(6):946-52.
- 35 18. Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M, Kappetein AP,
36 Van Dyck N, Mack M, Holmes D, Feldman T, Morice MC, Colombo A, Bass
37 E, Leadley K, Dawkins KD, van Es GA, Morel MA, Mohr FW. Assessment of
38 the SYNTAX score in the syntax study. *EuroIntervention.* 2009;5(1):50-56.
- 39 19. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek
40 JKJJ, Koolen JJ. Measurement of fractional flow reserve to assess the
41 functional severity of coronary-artery stenoses. *N Engl J Med*
42 1996;334(26):1703-1708.
- 43 20. Berwick DM. Avoiding overuse-the next quality frontier. *Lancet* 2017; S0140-
44 6736(16)32570-3.
- 45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Text Tables

Table 1. Baseline characteristics, cardiovascular risk factors, and history stratified by clinical indication.

	Stable CAD (n=352)	NSTEACS (n=88)	Overall (n=440)
Age (years)	69.3 (62.9-75.1)	71 (63.4-77.4)	69.6 (63-75.8)
Females <i>n</i> (%)	71 (20)	27 (31)	98 (22)
BMI (kg/m ²)	26.2 (24.2-28.9)	27 (24.6-30)	26.3 (24.2-29.3)
Creatinine (mg/dl)	0.9 (0.79,1.08)	0.97 (0.85, 1.18)	0.91 (0.8, 1.10)
SYNTAX score	12 (8-20)	15 (8-20)	13 (8-20)
CV Risk Factors			
Diabetes <i>n</i> (%)	173 (49)	43 (49)	216 (49)
Hypertension <i>n</i> (%)	262 (75)	71 (78)	333 (75)
Dyslipidemia <i>n</i> (%)	190 (54)	48 (55)	238 (54)
Active smoker <i>n</i> (%)	53 (15)	16 (18)	69 (16)
Prior Smoker <i>n</i> (%)	85 (24)	13 (15)	98 (22)
History of premature CAD <i>n</i> (%)	99 (28)	19 (22)	118 (27)
History			
Prior Angina <i>n</i> (%)	250 (71)	52 (59)	302 (69)
Prior MI <i>n</i> (%)	95 (27)	20 (23)	115 (26)
Prior PCI <i>n</i> (%)	148 (42)	28 (32)	176 (40)
Renal Insufficiency <i>n</i> (%)	38 (11)	20 (23)	58 (13)
Heart Failure <i>n</i> (%)	14 (4)	2 (2)	16 (4)
LVSD <i>n</i> (%)	23 (7)	8 (9)	31 (7)
COPD <i>n</i> (%)	26 (7)	8 (9)	34 (8)
Stroke <i>n</i> (%)	18 (5)	5 (6)	23 (5)
PAD <i>n</i> (%)	55 (16)	10 (11)	65 (15)

Legend. BMI, Body mass index; SYNTAX: synergy between percutaneous coronary intervention with TAXUS and cardiac surgery; SCAD: coronary artery disease; NSTEACS: non-ST elevation acute coronary syndrome; MI: myocardial infarction; PCI: percutaneous coronary intervention; LVSD: left ventricular systolic dysfunction defined as ejection fraction of 0.40 or less; COPD: Chronic obstructive pulmonary disease; PAD: peripheral artery disease.

Table 2. Characterization of the indication for PCI in patients with stable CAD (n=352).

Parameter	Value
Pre-Test Probability of CAD (%) [#]	69 (54-84)
Low (<15%) n (%)	0 (0)
Intermediate (15-85%) n (%)	222 (78)
High (>85%) n (%)	61 (22)
<i>Ad hoc</i> PCI n (%)	307 (87)
Any functional test of ischemia performed n (%) [*]	217 (62)
Exercise electrocardiography n	153
SPECT n	46
Stress echocardiography n	31
Stress cardiac magnetic resonance imaging n	3
Coronary computed tomographic angiography n (%)	27 (8)
No functional or anatomical testing n (%)	125 (35%)
AUC _{CORE} mappable	318 (90)
Appropriate n (%)	102 (32)
Uncertain n (%)	163 (51)
Inappropriate n (%)	52 (16)
AUC _{SITE} mappable	320 (91)
Appropriate n (%)	100 (31)
Uncertain n (%)	163 (51)
Inappropriate n (%)	57 (18)

[#]: Calculated according to (5) only in patients with unknown coronary anatomy (n=285): defined as a history of invasive coronary angiography or coronary computed tomography angiography in the year preceding the index PCI. ^{*}: Some patients (n=15) underwent more than 1 functional test before PCI 1 patient received 3 tests; SPECT: Single-Photon Emission Computed Tomography.

Author contributions:

Sergio Leonardi and Stefano De Servi: Study design, manuscript drafting, statistical analysis and critical revision.

Marcello Marino and Gabriele Crimi: angiographic core lab analysis, critical revision.

Florinda Maiorana, Diego Rizzotti: Data management, statistical analysis and critical revision

Corrado Lettieri, Luca Bettari, Marco Zuccari, Paolo Sganzerla, Simone Tresoldi, Marianna Adamo, Sergio Ghiringhelli, Carlo Sponzilli, Giampaolo Pasquetto, Andrea Pavei, Luigi Pedon, Luciano Bassan, Mario Bollati, Paola Camisasca, Daniela Trabattoni, Marta Brancati, Arnaldo Poli, Claudio Panciroli: critical Revision

Maddalena Lettino, Giuseppe Tarelli, Giuseppe Tarantini, Leonardo de Luca, Ferdinando Varbella: Central Heart Team and critical revision

Giuseppe Musumeci: Study design and critical revision

Competing interests


ICJME forms are available for all authors.

Dr Leonardi reports honoraria for advisory boards from AstraZeneca, Daiichi Sankyo, and The Medicines Company during the conduct of the study outside the submitted work; Dr. De Luca reports personal fees from Astra Zeneca, personal fees from Bayer, personal fees from Boehringer-Ingelheim, personal fees from

1
2
3 Eli Lilly and Daiichi Sankyo, personal fees from Menarini , personal fees from The
4 Medicines Company, outside the submitted work. Dr. De Servi reports personal
5 fees from Pfizer, personal fees from AstraZeneca, personal fees from Daichi-
6 sankyo, personal fees from Correvio, outside the submitted work. The other
7 authors report nothing to disclose. All authors have read and understood BMJ
8 policy on declaration of interests and have no other relevant interests to declare
9 in addition to these.
10

11 12 13 **Data Sharing Statement**

14 No additional unpublished data for this study will be available.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Histogram of Appropriate Use Score according to site-reported coronary anatomy (AUSSITE) in patients with and without diabetes.

220x176mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Boxplot of Appropriate Use Score according to ACL (AUSCORE) in patients who underwent and who did not underwent local heart team discussion, stratified by diabetes status.

220x176mm (72 x 72 DPI)

APPENDIX

Executive Committee and Medical Leadership

Stefano De Servi (study chair), Sergio Leonardi (principal investigator), Giuseppe Musumeci (GISE Lombardia President), Giuseppe Tarantini (GISE Veneto President).

Data management

Florinda Maiorana, Diego Rizzotti, Arianna Elia.

Central Heart Team

Maddalena Lettino, Giuseppe Tarelli, Ferdinando Varbella, Leonardo De Luca.

Angiographic Core Laboratory


Marcello Marino, Gabriele Crimi

Investigators

Maurizio Ferrario, *Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*; Corrado Lettieri, *ASST Mantova – Ospedale Carlo Poma, Mantova, Italy*; Maurizio D'urbano, Marco Zuccari *Ospedale Fornaroli di Magenta, Magenta, Italy*; Enrico Passamonti, Luca Bettari, Sergio Signore, *Ospedale di Cremona, Cremona, Italy*; Paolo Sganzerla, Mauro Rondi, *Ospedale di Treviglio e Caravaggio, Treviglio, Italy*; Planca Enrico, Simone Tresoldi, *Azienda Ospedaliera di Desio e Vimercate, Vimercate, Italy*; Federica Etori, Marianna Adamo, *Spedali Civili di Brescia, Brescia, Italy*; Sergio Ghiringhelli, *Ospedale di Circolo Fondazione Macchi, Varese, Italy*; Carlo Sponzilli, *Ospedale San Paolo, Milano, Italy*; Giuseppe Musumeci, Federica Piazzoni, *ASST – Papa Giovanni XXIII- Bergamo, Italy*; Giampaolo Paschetto, Michela Facchin, *Ospedali Riuniti Padova Sud Madre Teresa di Calcutta, Monselice, Italy*; Andrea Pavei, Gerlando Preti, *Presidio Ospedaliero di Conegliano, Conegliano, Italy*; Luigi Pedon, *Presidio Ospedaliero di Cittadella, Cittadella, Italy*; Luciano Bassan, *ULSS 4 Alto Vicentino, Thiene, Italy*; Francesco Bedogni, Mario Bollati, Luca Testa, Giovanni Bianchi, *IRCCS Policlinico San Donato, San Donato Milanese, Italy*; Paola Camisasca, *Ospedale San Gerardo, Monza, Italy*; Daniela Trabattoni, *Centro Cardiologico Monzino, Milano, Italy*; Ornella Leonzi, Marta Brancati, *Fondazione Poliambulanza, Brescia, Italy*; Arnaldo Poli, Katia Stefanin, *ASST Ovest Milanese, Legnano, Italy*; Claudio Panciroli, Emanuele Prina, *ASST di Lodi, Lodi, Italy*; Paolo Pagnotta, Daniela Cattani, *IRCCS Humanitas, Rozzano (MI), Italy*; Giuseppe Tarantini, Ervis Hiso, *Ospedale Di Padova, Padova, Italy*.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure



peer review only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	Indicate the study's design with a commonly used term in the title or the abstract (Title Page)
		(a)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found (Abstract Page 2)
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported (Introduction, page 4)
Objectives	3	State specific objectives, including any prespecified hypotheses (Objective, abstract)
Methods		
Study design	4	Present key elements of study design early in the paper (Study Design, page 5)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection (Methods, page 5 and Results, page 11)
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants (Methods, page 5, Patient Selection Section)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable (Methods, page 5)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group (Methods, page 5 Data Collection Section)
Bias	9	Describe any efforts to address potential sources of bias (Methods, page 5)
Study size	10	Explain how the study size was arrived at (Sample Size Consideration, page 10)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why (Statistical Section for all below, page 10)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (Results, page 11) (b) Give reasons for non-participation at each stage (NA) (c) Consider use of a flow diagram (NA)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (Results, page 11) (b) Indicate number of participants with missing data for each variable of interest (Results, page 11)
Outcome data	15*	Report numbers of outcome events or summary measures (Results, page 11)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were

		adjusted for and why they were included (Results, page 11)
		(b) Report category boundaries when continuous variables were categorized (Results, page 11)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period (Results, page 11)
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses (Results, page 11)
Discussion		
Key results	18	Summarise key results with reference to study objectives (Discussion, page 15)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias (Discussion, page 15)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence (Discussion, page 15)
Generalisability	21	Discuss the generalisability (external validity) of the study results (Discussion, page 15)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based (Funding Statement, page 10)

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

APpropriateness of percutaneous Coronary interventions in patients with ischemic HEart disease in Italy: The APACHE Pilot study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016909.R1
Article Type:	Research
Date Submitted by the Author:	19-Jun-2017
Complete List of Authors:	<p>Leonardi, Sergio; Fondazione IRCCS Policlinico San Matteo, Marino, Marcello; Aziende Socio Sanitarie Territoriale di Crema Crimi , Gabriel ; Fondazione IRCCS Policlinico San Matteo, Maiorana, Florinda; Fondazione IRCCS Policlinico San Matteo Rizzotti, Diego; Fondazione IRCCS Policlinico San Matteo Lettieri, Corrado; Azienda Socio Sanitaria Territoriale di Mantova Bettari, Luca; Azienda Socio Sanitaria Territoriale di Cremona Zuccari, Marco</p> <p>Sganzerla, Paolo; Agenzia di Tutela della Salute di Bergamo Ovest Tresoldi, Simone ; Azienda Ospedaliera di Desio e Vimercate Adamo, Marianna; Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</p> <p>Ghiringhelli, Sergio; Ospedale di Circolo e Fondazione Macchi Sponzilli, Carlo; Ospedale San Paolo</p> <p>Pasquetto, Giampaolo; Presidio Ospedaliero di Monselice</p> <p>Pavei, Andrea; Presidio di Conegliano</p> <p>Pedon, Luigi; Presidio Ospedaliero di Cittadella</p> <p>Bassan, Luciano; Azienda ULSS 4 Alto Vicentino</p> <p>Bollati, Mario; IRCCS Policlinico San Donato</p> <p>Camisasca, Paola; Azienda Ospedaliera San Gerardo</p> <p>Trabattoni, Daniela; Centro Cardiologico Monzino</p> <p>Brancati, Marta; Fondazione Poliambulanza Istituto Ospedaliero Poli, Arnaldo; Aziende Socio Sanitarie Territoriale Ovest Milanese Panciroli, Claudio</p> <p>Lettino, Maddalena; Istituto Clinico Humanitas</p> <p>Tarelli, Giuseppe; Istituto Clinico Humanitas</p> <p>Tarantini, Giuseppe; Azienda Ospedaliera di Padova</p> <p>De Luca, Leonardo; Ospedale di Tivoli</p> <p>Varbella, Ferdinando; 1Cardiology Unit, Ospedale degli Infermi, Musumeci, Giuseppe; Azienda Ospedaliera S Croce e Carle Cuneo</p> <p>De Servi, Stefano; IRCCS Sesto San Giovanni</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Health services research
Keywords:	Coronary heart disease < CARDIOLOGY, Percutaneous Coronary Intervention, Multidisciplinary Decision Making

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For peer review only

Appropriateness of percutaneous Coronary interventions in patients with ischemic HEart disease in Italy: The APACHE Pilot study

Sergio Leonardi, MD, MHS, FESC¹ Marcello Marino, MD² Gabriele Crimi, MD¹
Florinda Maiorana, MSc,¹ Diego Rizzotti, MSc¹ Corrado Lettieri, MD³ Luca Bettari,
MD⁴ Marco Zuccari, MD⁵ Paolo Sganzerla, MD⁶ Simone Tresoldi, MD⁷ Marianna
Adamo, MD⁸ Sergio Ghiringhelli, MD⁹ Carlo Sponzilli, MD¹⁰ Giampaolo Pasquetto,
MD¹¹ Andrea Pavei, MD¹² Luigi Pedon, MD¹³ Luciano Bassan, MD¹⁴ Mario Bollati,
MD¹⁵ Paola Camisasca, MD¹⁶ Daniela Trabattoni, MD¹⁷ Marta Brancati, MD¹⁸ Arnaldo
Poli, MD¹⁹ Claudio Panciroli, MD²⁰ Maddalena Lettino, MD²¹ Giuseppe Tarelli²¹, MD
Giuseppe Tarantini, MD²² Leonardo De Luca, MD²³ Ferdinando Varbella, MD²⁴,
Giuseppe Musumeci, MD²⁵ and Stefano De Servi, MD, FESC²⁶.

- 1: Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 2: Ospedale Maggiore di Crema, Crema, Italy
- 3: ASST Mantova – Ospedale Carlo Poma, Mantova, Italy
- 4: ASST Cremona – Ospedale di Cremona, Cremona, Italy
- 5: Ospedale Fornaroli di Magenta, Magenta, Italy
- 6: ASST Bergamo ovest – Ospedale di Treviglio, Italy
- 7: Azienda Ospedaliera di Desio e Vimercate, Vimercate, Italy
- 8: Spedali Civili di Brescia, Brescia, Italy
- 9: Ospedale di Circolo Fondazione Macchi, Varese, Italy
- 10: Ospedale San Paolo, Milano, Italy
- 11: Ospedali Riuniti Padova Sud Madre Teresa di Calcutta, Monselice, Italy
- 12: Presidio Ospedaliero di Conegliano, Conegliano, Italy
- 13: Presidio Ospedaliero di Cittadella, Cittadella, Italy
- 14: ULSS 4 Alto Vicentino, Thiene, Italy
- 15: IRCCS Policlinico San Donato, San Donato Milanese, Italy
- 16: Ospedale San Gerardo, Monza, Italy
- 17: Centro Cardiologico Monzino, Milano, Italy
- 18: Fondazione Poliambulanza, Brescia, Italy
- 19: ASST Ovest Milanese, Legnano, Italy
- 20: ASST di Lodi, Lodi, Italy
- 21: Humanitas Research Hospital, Rozzano (MI), Italy
- 22: Ospedale di Padova, Padova, Italy
- 23: Ospedale San Giovanni Evangelista, Tivoli (Rome), Italy
- 24: Ospedale degli Infermi, Rivoli, Italy
- 25: ASST – Papa Giovanni XXIII- Bergamo, Italy
- 26: IRCCS MultiMedica, Milano, Italy

Word Count: 4093

Address for correspondence

Sergio Leonardi, MD, MHS, FESC
Fondazione IRCCS Policlinico S. Matteo
Viale Golgi 19
27100
Pavia, Italy
S.Leonardi@smatteo.pv.it

Abstract *Word count: 305*

Objectives: To first explore in Italy appropriateness of indication, adherence to guideline recommendations, and mode of selection for coronary revascularization.

Design: Retrospective, pilot study.

Setting: Twenty-two percutaneous coronary intervention (PCI)-performing hospitals (20 patients/site), 13 (59%) with on-site cardiac surgery.

Participants: 440 patients who received PCI for stable coronary artery disease (CAD) or non-ST elevation acute coronary syndrome were independently selected in a 4:1 ratio with half diabetics.

Primary and Secondary Outcome Measures: Proportion of patients who received appropriate PCI using validated appropriate use scores (ie AUS ≥ 7). Also, in patients with stable CAD, we examined adherence to the following ESC recommendations: a) % of patients with complex coronary anatomy treated after heart-team discussion; b) % of fractional flow reserve-guided PCI for borderline stenoses in patients without documented ischemia; c) % of patients receiving guideline-directed medical therapy at the time of PCI as well as use of provocative test of ischemia according to pre-test probability (PTP) of CAD.

Results: Of the 401 mappable PCIs (91%), 38.7% (95%CI: 33.9-43.6) were classified as appropriate, 47.6% (95%CI: 42.7-52.6) as uncertain, and 13.7% (95%CI: 10.5-17.5%) as inappropriate. Median PTP in stable CAD patients without known coronary anatomy was 69% (78% intermediate PTP, 22% high PTP). Ischemia testing use was similar ($p=0.71$) in patients with intermediate ($n=140$, 63%) and with high PTP ($n=40$, 66%). In patients with stable CAD ($n=352$) guideline adherence to the 3 recommendations explored was: a) 11%; b) 25%; c) 23%. AUS was higher in patients

1
2
3 evaluated by the heart team as compared to patients who were not [7 (6,8) vs 5 (4,7);
4
5 P=0.001].
6

7 **Conclusions:** Use of heart-teams approaches and adherence to guideline
8
9 recommendations on coronary revascularization in a real world setting is limited. This
10
11 pilot study documents the feasibility of measuring appropriateness and guideline
12
13 adherence in clinical practice and identifies substantial opportunities for quality
14
15 improvement.
16
17

18 **Study Registration:** NCT02748603.
19
20
21
22
23
24

25 **Strengths and limitations of this study**

26

- 27 • APACHE is a first-in-class study in Italy designed to measure the degree of
28 appropriateness of indication, multi-disciplinary decision-making processes, and
29 implementation of key guideline recommendations in patients undergoing PCI.
30
- 31 • This study, that enrolled patients with stable CAD and diabetes, was intentionally
32 designed to focus on high-risk patients for inappropriate PCI. Therefore true
33 appropriateness of PCI may be underestimated. However, rather than an
34 epidemiological study, APACHE intention was to serve as first initiative
35 sponsored by a national medical society to measure care process and improve
36 quality.
37
- 38 • APACHE examined the appropriateness of PCI indication, not of coronary
39 angiography. Therefore we acknowledge as a limitation that we have no data to
40 inform appropriateness of surgical revascularization, nor indication to invasive
41 angiography.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Percutaneous coronary intervention (PCI) has dramatically improved the prognosis of patients with coronary artery disease (CAD). Yet, many patients receive PCI whose clinical indication appears uncertain or inappropriate, especially in the non-acute setting.^{1,2} The development of appropriate use criteria by cardiovascular societies has provided the basis for a standardized approach to systematically assess the clinical appropriateness of PCI³ and has produced a reduction of the volume of non-acute PCI as well as an increase in the proportion of procedures classified as appropriate⁴ but these studies have been mostly performed in the US.

In Europe, data on appropriateness of indication and mode of selection for coronary revascularization strategies as well as the degree of implementation of guideline recommendations are limited.⁵ European Society of Cardiology (ESC) guidelines^{6,7} urge the implementation of a multidisciplinary decision-making approach – the heart team – to select the optimal mode of revascularization but data on the implementation of this process in patients with complex coronary artery disease (CAD), including those with stable CAD and diabetes, are scarce.⁸ Specifically the ESC^{6,7} recommend that 1) complex pathologies in stable patients, including lesions of the left main or proximal left anterior descending artery (LAD) and three-vessel disease, should in general not be treated *ad hoc*, but discussed by the heart team; 2) pressure derived fractional flow reserve (FFR) should be used to identify haemodynamically relevant coronary lesion(s) in stable patients when evidence of ischaemia is not available; and 3) patients with stable CAD must receive guideline-recommended medical treatment prior to revascularization.

We designed the APpropriAteness of percutaneous Coronary interventions in patients with ischemic HEart disease – APACHE Pilot study to first explore the degree of appropriateness of indication of PCI, multi-disciplinary decision-making

1
2
3 processes, and implementation of key guideline recommendations in patients
4
5 undergoing PCI in Italy.
6
7

8 9 **Methods**

10 11 **Study Design and Patient Selection**

12 APACHE was designed as a pilot initiative to assess appropriateness of PCI
13
14 indication and adherence to key guideline recommendations on coronary
15
16 revascularization in patients with predominantly stable CAD and diabetes, considered
17
18 to be at high risk for inappropriate indication and mode for coronary revascularization
19
20 (ie PCI treatment in patients with an indication for CABG). All PCI performing
21
22 hospitals of the Lombardia and Veneto region in Italy, serving a population of \approx
23
24 15.000.000 people, were invited to participate in the study. Twenty-two sites agreed
25
26 to participate, obtained regulatory approval, and were eventually included.
27
28

29
30 At each participating hospital, 20 patients were independently selected on-site
31
32 by the study team (see online appendix) among consecutive patients who were
33
34 admitted in the previous year for an elective procedure to treat stable CAD or urgently
35
36 for an episode of non-ST elevation acute coronary syndrome in a 4:1 ratio without site
37
38 personnel involvement in the selection of the cases identified to minimize selection
39
40 bias. The study population was also selected to preserve an overall 1:1 ratio on
41
42 diabetes status. If the number of patients selected was insufficient older cases were
43
44 evaluated for possible inclusion. Due to the low likelihood of receiving a *redo*
45
46 procedure as well as the inability to measure a SYNTAX score, patients with a history
47
48 of bypass surgery were excluded.
49
50
51
52

53 54 **Data Collection, Core Angiographic Assessment, and Central Heart Team**

55 Variables of interest were collected by the study team during dedicated visits
56
57 at participating hospitals via clinical chart abstraction. Sites were requested to provide
58
59
60

1
2
3 the complete clinical chart, including the coronary angiogram of the index PCI.
4
5 Source documentation was reviewed in full to abstract symptoms status (angina
6
7 class); cardiovascular risk factors and comorbidities; medical therapy at time of PCI;
8
9 site-reported indication for PCI; presence, results, and timing of any noninvasive
10
11 functional test, fractional flow reserve (FFR) or intracoronary imaging, if performed;
12
13 coronary anatomy and reported significance of angiographic stenoses for treated
14
15 lesion(s) on the catheterization report; and evidence for heart-team discussion
16
17 involving a cardiac surgeon. Finally, pretest probability (PTP) of significant coronary
18
19 artery disease was calculated in patients with stable CAD according to guideline
20
21 recommendations ⁷.
22
23
24

25 The Angiographic Core Laboratory (ACL) was composed by two independent
26
27 physicians with experience in interventional cardiology (MM, GC) who centrally and
28
29 independently reviewed coronary angiography for each patient to define 1) baseline
30
31 SYNTAX score 2) category of coronary anatomy (eg. one, two or three-vessel CAD
32
33 with or without proximal LAD involvement) ³ and 3) presence of “borderline”
34
35 angiographic stenoses (50% to 60%). For the SYNTAX score a disagreement was
36
37 arbitrarily considered to be present if there was a between score difference ≥ 10 or
38
39 both scores were not in the same tertile (0-22, 23-32, >32). In case of agreement an
40
41 average SYNTAX score was calculated. In case of disagreement between reviewers
42
43 the case was first resolved by consensus. If a consensus could not be reached (or if the
44
45 case was deemed particularly challenging) the conflict was resolved by the central
46
47 heart team. Anatomical category and presence of borderline coronary stenoses were
48
49 analyzed by a single reviewer (GC or MM).
50
51
52
53

54 The central heart team was represented by four members – two interventional
55
56 cardiologists (LDL, FV), one cardiac surgeon (GT), and one clinical cardiologist
57
58
59
60

(ML) – nominated by the Italian Society of Interventional Cardiology (SICI-GISE) among recognized experts in their respective specialty. The role of the central heart team was to review cases with unresolved conflicts by the ACL, cases considered complex or challenging by the study team or cases with incomplete or conflicting documentation. Assessments of the central heart team were performed by consensus.

Evaluation of Appropriateness of Indications for Coronary Revascularization

The comprehensive documentation of indications for PCI was formally examined based on the 2013 ACC/AHA/SCAI/AMA-PCPI/NCQA Percutaneous Coronary Intervention Measurement Set.⁹ This diagnostic measure was defined as the proportion of patients whose clinical documentation includes, at a minimum, the following elements:

1. Priority (acute coronary syndrome, elective, urgent, emergency/salvage); 2. Presence and severity of angina symptoms (eg, Canadian Cardiovascular Society classification system); 3. Use of antianginal medical therapies within 2 weeks before the procedure, if any; 4. Presence, results, and timing of noninvasive stress test, FFR, or intravascular ultrasound, if performed; and 5. Significance of angiographic stenosis on coronary angiography for treated lesion.

Appropriateness of indication of coronary revascularization was examined by assigning to each procedure an appropriate use score (AUS), with a score of 1 indicating a completely inappropriate procedure to a score of 9 indicating a completely appropriate one.³ Scores of 7 to 9 indicate that revascularization is considered generally appropriate and likely to improve patients' symptoms or survival. Scores of 1 to 3 considered generally inappropriate while scores of 4 to 6 indicate a clinical scenario for which the likelihood that coronary revascularization will improve health outcomes or symptoms is uncertain. This score was defined by

1
2
3 considering clinical presentation; severity of angina; extent of ischemia on
4
5 noninvasive testing; presence of other prognostic factors, such as congestive heart
6
7 failure or depressed left ventricular function; extent of medical therapy at the time of
8
9 PCI; and extent of anatomic coronary disease. If the scenario was not considered by
10
11 the consensus document,³ the procedure was considered non mappable.
12

13
14 To limit site operator-related bias, the study team calculated two scores for
15
16 each procedure:
17

- 18 1. AUS_{SITE}, based on site-reported extent of anatomic coronary disease;
- 19 2. AUS_{CORE}, based on ACL reported extent of anatomic coronary disease.
20
21
22

23 Evaluation of adherence to ESC Guidelines and Heart Team Processes

24
25 In patients with stable CAD we assessed adherence to three class I recommendations
26
27 according to ESC guidelines^{6,7}:
28
29

30 **Recommendation 1:** Proportion of patients with stable CAD and complex anatomy
31
32 [including lesions of the left main, proximal left anterior descending (LAD) and/or
33
34 three-vessel CAD] who were treated after local heart team discussion. This
35
36 recommendation was explored using both site-reported and ACL-reported coronary
37
38 anatomy. We also explored adherence to this recommendation by calculating the
39
40 proportion of patients with complex anatomy who received *ad hoc* PCI without
41
42 documented heart team discussion. To better define optimal mode of coronary
43
44 revascularization, the SYNTAX II score¹⁰ as well as the Society of Thoracic
45
46 Surgeons (STS)¹¹, and EuroScore II¹² were calculated.
47
48
49

50 **Recommendation 2:** Proportion of patients with stable CAD, no evidence of
51
52 ischemia, and borderline lesions according to the ACL in whom FFR was used to
53
54 identify haemodynamically relevant coronary lesion(s).
55

56 Specifically, this recommendation was explored as follows:
57
58
59
60

- 1
2
3 a) Proportion of patients with no functional test (ie test negative or not performed)
4 and at least one borderline stenosis according to ACL in whom pressure-derived
5 FFR was used;
6
7
8
9
10 b) Proportion of patients with no functional test or asymptomatic and at least one
11 borderline stenosis according to ACL in whom pressure derived FFR was used;
12
13
14 c) Proportion of patients with no functional test or asymptomatic and site-reported
15 multivessel CAD in whom pressure derived FFR was used.¹³
16
17

18 **Recommendation 3:** Proportion of patients with stable CAD who received guideline-
19 directed medical therapy prior to revascularization.⁷
20
21

22 Specifically:
23

- 24 a) Proportion of patients without known allergy or documented intolerance
25 taking low dose aspirin (75-150 mg daily) or clopidogrel;
26
27
28 b) Proportion of patients without known allergy or documented intolerance
29 receiving a statin;
30
31
32 c) Proportion of patients with heart failure, hypertension or diabetes treated with
33 an ACE-inhibitor or angiotensin receptor blocker;
34
35
36 d) Proportion of patients on optimal medical therapy defined as drugs for event
37 prevention (aspirin and/or clopidogrel; a statin; an ACE-I/ARB if heart failure,
38 hypertension or diabetes) plus at least one drug for angina relief if
39 symptomatic, such as beta-blockers, calcium channel blockers, long acting
40 nitrates, ivabradine, or ranolazine.
41
42
43
44
45
46
47
48

49 In patients with NSTEMACS, we examined the proportion of PCI procedures
50 performed within 24 hours of admission in patients with a Global Registry of Acute
51 Coronary Events (GRACE) score > 140.
52
53
54
55
56
57
58
59
60

1
2
3 Finally we assessed, by structured investigators surveys, the presence of
4 written institutional protocols developed locally by the Heart Team in accordance
5 with current guidelines including specific anatomical criteria and clinical subsets that
6 may be (or should not be) treated *ad hoc* as well as the modalities and timing for
7 convocation of heart team meetings.
8
9
10
11
12

13 **Statistical Analysis and Sample Size Considerations**

14
15
16 Categorical data are presented as counts and proportion and continuous data as
17 median (25th, 75th percentile) and were analyzed, as appropriate, using chi-square (or
18 Fisher's exact) and Wilcoxon rank-sum test. We calculated 95% confidence intervals
19 for the proportion using the normal approximation to the binomial calculation. To
20 control for the effect of participating site as well as the presence of cardiac surgery
21 on-site on the primary outcome (AUS), we used ANOVA generalized linear model
22 procedures including participating site and presence of cardiac surgery on-site as a
23 covariates for the key subgroup (factor) of interest (ie. patients evaluated by the heart
24 team vs not).
25
26
27
28
29
30
31
32
33
34
35

36
37 Given the lack of prior studies to estimate appropriateness of coronary
38 revascularization in Italy, sample size estimation was challenging. The study was
39 powered on the primary subgroup of interest, patients with stable CAD, assuming an
40 appropriateness of 35% in this patient population based on prior reports.⁴ Using a
41 normal approximation to the binomial distribution for this proportion a population of
42 350 stable CAD patients was needed to obtain a 95% confidence interval between
43 30% and 40% for appropriateness.¹⁴ The study obtained institutional review board
44 approval by all participating hospitals and is registered on ClinicalTrials.gov ID:
45 NCT02748603.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sponsor and Funding

The APACHE study was designed by the chair and principal investigator and approved by the institutional review board at each participating center. The study was sponsored by the Italian Society of Invasive Cardiology (SICI-GISE), a nonprofit organization, and received unrestricted grant support from the Abbott Vascular and Daiichi-Sankyo. The sponsor and funders had no role in the design of the study, the collection, monitoring, analysis, and interpretation of the data, or the writing of the report. The first draft of the manuscript was written by the first author. All the authors vouch for the accuracy and completeness of the data and all analyses.

Results

Of the 22 hospitals included, 13 (59%) have onsite cardiac surgery and 4 (18%) are private hospitals. Overall, PCI procedures of 440 patients (performed between January 2014 and May 2016) were included: 352 for patients with stable CAD and 88 with NSTEMI [12 with unstable angina and 76 with non-ST elevation myocardial infarction; median GRACE score 109 (89.5, 125.5), median Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) score 24 (16,40)]. A SYNTAX score could be calculated in 422 patients (96%) with 87 disagreements (21%) between ACL reviewers. Of these, 55 were resolved by consensus and 32 by the central heart team. Clinical profile of the selected patients stratified by clinical indication is showed in **Table 1**. By design, \approx half of the patients had diabetes (n=216, 49.1%) with a high proportion of patients with dyslipidemia (54%), prior PCI (40%) and history of angina (69%). **Table 2** presents data on indication and test selection in patients with stable CAD. Median PTP of CAD in stable CAD patients without known coronary anatomy was 69% (78% intermediate PTP, 22% high PTP, no patient with low PTP). The use of provocative tests of ischemia was similar

($p=0.71$) in patients with intermediate ($n=140$, 63%) and with high PTP ($n=40$, 66%). Of the 88 patients with NSTEMI, a GRACE score > 140 was present in 11 (12%) patients. Of these, 5 patients had PCI within 24 hours.

Comprehensive Documentation and Appropriateness of Indications for Coronary Revascularization

A comprehensive documentation of PCI indication was present in 427 (97%) patients. Most common reasons for unfulfilling this diagnostic measure were the lack of documentation in the clinical chart of any non-invasive testing, both functional and imaging ($n=5$) or missing information on therapy at admission ($n=8$).

An AUS_{SITE} could be calculated in 405 (92%) of patients while the remaining 35 patients did not have comprehensive documentation of indications for PCI or the scenario was not applicable (ie non mappable AUC). The median AUS_{SITE} was 6 (5,7) corresponding to 153 (37.8%, 95%CI: 33.1-43.5) of PCI classified as appropriate, 193 (47.7%, 95%CI: 42.8-52.5) as uncertain, and 59 (14.6%, 95%CI: 11.1-18) as inappropriate AUC, similar in patients with a and without diabetes (**Figure 1 and Figure 2A**). AUS_{SITE} was higher in patients evaluated by the local heart team as compared to patients who were not, both in unadjusted [7 (5,8) vs 5 (4,7); $p=0.003$] and adjusted analysis (mean AUS_{SITE} 7.0, SD 1.8 vs 5.7 SD 1.9; $p=0.001$; participating site and cardiac surgery on-site both NS).

An AUS_{CORE} could be calculated in 401 patients (91%). Of these, 23 (6%) required a review by the central heart team. Median AUS_{CORE} was 6 (5,7) with 155 (38.7%, 95%CI:33.9-43.4) of PCI classified as appropriate, 191 (47.6%,95%CI: 42.7-52.5) as uncertain, and 55 (13.7%,95%CI:10.3-17.1) as inappropriate AUC. AUS_{CORE} results by site and in key subgroups are reported in the **Figure 2B** and the **Supplementary Figure respectively**. AUS_{CORE} was higher in patients with

1
2
3 NSTEACS as compared to patients with stable CAD with no significant difference
4
5 according to diabetic status or type of hospitals. AUS_{CORE} was higher in patients
6
7 evaluated by the local heart team as compared to patients who were not both in
8
9 unadjusted [7 (6,8) vs 5 (4,7); p=0.001] and adjusted analysis (mean AUS_{CORE} 7.1,
10
11 SD 1.5 vs 5.8 SD 1.9; p=0.001; participating site and cardiac surgery on-site both
12
13 NS). (Figure 3).
14
15

16 17 **Recommendation 1: Proportion of stable CAD patients with complex** 18 **pathologies who were treated after heart team discussion**

19
20 Of the 352 patients with stable CAD, 148 (42%) had a complex site-reported
21
22 coronary anatomy including significant lesions of the left main (n=16), proximal LAD
23
24 (n=73) and three-vessel disease (n=59). Of these, 17 (11%) underwent local heart
25
26 team discussion. Median operative mortality was low-to-intermediate as estimated by
27
28 both the Euroscore II [1.15 % (0.64, 2.05)] and the STS score [0.92% (0.45,1.81)].
29
30 Also, 118 of the 148 patients with complex site-reported coronary anatomy (80%)
31
32 received *ad hoc* PCI without evidence of discussion with the local heart team in the
33
34 clinical chart, with no difference in patients treated at hospitals with or without on-site
35
36 cardiac surgery (p=0.74). The proportion of patients with complex coronary lesions
37
38 according to the ACL was 46% (n=164). Of these, 20 (12%) underwent local heart
39
40 team discussion and 124 (75%) were treated *ad hoc* without evidence of heart team
41
42 discussion.
43
44
45

46
47 The median SYNTAX score in patients with stable CAD was 12 (8-20), with
48
49 83% of patients with a score < 23, 13% between 23 and 32, and 4% above 32.

50
51 A SYNTAX II score could be calculated in 337 cases (96%). Of these, CABG
52
53 was the recommended option for 40 patients (12%), PCI the recommended option for
54
55 14 (4%), and either mode of revascularization was recommended in the remaining
56
57 283 cases (84%). Of the 40 patients where SYNTAX II score recommended CABG a
58
59
60

1
2
3 local heart team discussion was performed in 3 cases (7%). Finally, a total of 75
4
5 stable CAD patients (21%) with diabetes and multi-vessel CAD underwent *ad hoc*
6
7
8 PCI without local heart team discussion documented in the patient's chart.
9

10
11 **Recommendation 2: Proportion of stable CAD patients with no evidence of**
12 **ischemia where pressure derived fractional flow reserve (FFR) was used to**
13 **identify haemodynamically relevant coronary lesion(s).**
14

15
16 Of the 352 patients with stable CAD, 151 (43%) had no objective evidence of
17
18 ischemia (135 patients had no provocative test of ischemia, 8 had negative testing and
19
20 8 inconclusive testing), 36 (10%) were asymptomatic and 82 (23%) had multi-vessel
21
22 CAD according to the site. A pressure-derived FFR to guide PCI was used for 29
23
24 patients (8.2%) with stable CAD while intravascular ultrasound for 12 patients (3%).
25
26 No PCI were guided by coronary optical coherence tomography.
27

28
29 Of the 151 patients with no evidence of ischemia, the ACL identified 28
30
31 patients (18%) with at least one borderline coronary lesion treated with PCI with FFR
32
33 performed in 7 of these 28 cases (25%).
34

35
36 Of the 175 (50%) patients who had no objective evidence of ischemia or were
37
38 asymptomatic, 33 borderline lesions were identified by the ACL with FFR performed
39
40 in 10 cases. In the subgroup of 91 patients who also had site-reported multi-vessel
41
42 CAD, 13 borderline lesions were identified by the ACL, with FFR performed in 4
43
44 cases.
45

46
47 **Recommendation 3: Use of guideline-directed medical therapy at the time of**
48 **PCI in patients with stable CAD**
49

50
51 Of the 352 patients with stable CAD, 299 (85%) were treated with single
52
53 antiplatelet therapy at the time of angiography (292 low-dose aspirin and 7 with
54
55 clopidogrel) and 20 (6%) received dual antiplatelet therapy with aspirin and
56
57 clopidogrel (only 1 reported case of aspirin intolerance who successfully underwent
58
59
60

1
2
3 aspirin desensitization); 266 (76%) were on a statin (no reported case of statin
4 intolerance); 202 (57%) received an ACE-I or an angiotensin receptor blocker (no
5 reported case of allergy or intolerance). Among the subgroup of stable CAD patients
6 with hypertension, heart failure (or asymptomatic left ventricular ejection fraction of
7 40% or less), or diabetes (N=265; 75% of the overall stable CAD population), a
8 treatment with ACE-I or ARB was given to 176 patients (66%). Finally, a therapy
9 with an anti-anginal agent (beta-blocker, calcium channel blocker, nitrates,
10 ivabradine, or ranolazine) was administered to 237 patients overall and to 169 patients
11 of the 248 with symptoms of angina (68%). Overall a total of 100 patients (23%)
12 received guideline-directed medical therapy at time of PCI.
13
14
15
16
17
18
19
20
21
22
23
24

25 26 **Adoption of institutional heart-team protocols**

27 Investigators from all participating centers (n=22) were interviewed and all
28 responded. A written institutional heart-team protocol was available in 5 (23%)
29 centers (1 with on-site cardiac surgery, 4 without on-site cardiac surgery) while in
30 other 5 centers (3 with on-site cardiac surgery) heart team meetings were being
31 scheduled on a regular basis (usually weekly). All other hospitals (n=12) did not have
32 either a heart team institutional protocol or regularly planned heart team meetings.
33
34
35
36
37
38
39
40
41

42 **Discussion**

43 In this pilot investigation we assessed appropriateness of indication of
44 coronary revascularization and adherence to key guideline recommendations in a real
45 world population with a high prevalence of stable CAD and diabetes as well as
46 multidisciplinary decision-making processes. We identified important gaps in
47 implementations of guideline recommendations and opportunities to improve the care
48 patients undergoing PCI.
49
50
51
52
53
54
55
56
57
58
59
60

Considerations on Appropriateness of Indication for Coronary Revascularization

The proportion of appropriate indication for coronary revascularization was 39% in the overall population and 32% in patients with stable CAD with similar rates observed using local vs ACL anatomical category. These proportions are similar to what was observed in the US when AUC were first released in 2009.^{4,15} As expected, appropriateness was higher in patients with NSTEMI as compared to patients with stable CAD but similar according to diabetes status as well as in hospitals with and without on-site cardiac surgery. Importantly both AUS_{SITE} and AUS_{CORE} were significantly higher in patients who were evaluated by a heart team suggesting multi-disciplinary decision-making is a surrogate of optimal revascularization choice.

In patients with stable CAD a functional testing strategy (used in 62% of patients) was far more common than an anatomical-testing strategy with coronary CTA (used only for 8% of patients), in agreement with the neutral findings of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.¹⁶ Notably, the use of functional testing was similar in patients with intermediate and with high PTP of significant CAD suggesting that the determination of PTP, considered the first major step in clinical decision making in this patient population,⁷ has limited influence in the real world to define a diagnostic strategy. Also, 33% of stable CAD patients with unknown coronary anatomy had neither functional nor anatomical testing before PCI and only 38% had maximal anti-ischemic medical therapy before PCI, proportions that have contributed to the observed suboptimal appropriateness and call for implementation of quality improvements initiatives. Indeed, it has been observed that most (55.5%) of Medicare patients with stable CAD do not have documentation of ischemia by noninvasive testing prior to elective PCI and that pre-PCI stress testing was associated with lower mortality in patients

1
2
3 undergoing elective PCI.^{17,18} Overall these findings suggest a need to focus on PTP
4
5 assessment in decision-making, appropriate classification of risk by non-invasive
6
7 tests, and optimization of medical therapy before PCI.
8
9

10 Adherence to and Implementation of ESC Guidelines

11
12 To explore potential “specialty bias” – ie PCI treatment in patients with an
13
14 indication for CABG – we examined the proportion of patients with complex
15
16 coronary lesions, including significant disease of the left main, proximal LAD, and/or
17
18 three-vessel disease, who were treated *ad hoc* without evidence of heart team
19
20 discussion in the medical charts. We observed that only \approx one of ten eligible patients
21
22 underwent heart team discussion and 75 to 80% of patients with complex coronary
23
24 anatomy were treated *ad hoc*, with no significant differences in sites with and without
25
26 on-site cardiac surgery. To further explore this, we surveyed investigators to better
27
28 understand local decision-making processes. We observed that most sites did not have
29
30 a written institutional protocol and decision of heart team convocation was left at the
31
32 discretion of the interventional cardiologist on call. The high proportion of *ad hoc*
33
34 PCI in patients with complex disease together with the lack of structured local heart
35
36 teams identify a substantial opportunity to improve multidisciplinary decision making
37
38 processes and indicate the need for standardized institutional protocols, that 1) should
39
40 avoid the need for the systematic case-by-case review of all diagnostic angiograms
41
42 but guide the management of complex cases 2) define standards for heart team
43
44 composition and roles, and 3) generate consensus on practical ways to implement
45
46 them.
47
48
49
50
51

52
53 The SYNTAX score is also considered by the guidelines to inform choice on
54
55 optimal type of revascularization. This score, which relies on subjective assessment of
56
57 lesions using coronary angiography, is well known to have limited reproducibility.¹⁹
58
59
60

1
2
3 The highest kappa value observed in a study of the SYNTAX investigators to assess
4 intra-observer variability was 0.54, and only 0.36 for bifurcations¹⁹ and inter-
5 observer reproducibility was even lower.²⁰ We therefore decided to adopt a
6 conservative approach to define a disagreement between reviewers (arbitrarily defined
7 as a difference of at least 10 points or change of tertile) but still observed a
8 disagreement in 21% of patients. This variability suggests that for clinical decision-
9 making SYNTAX score should not be used in isolation but rather integrated with
10 clinical data. The SYNTAX II score was developed to address this need. By
11 implementing this score in the APACHE population, we observed that in the vast
12 majority of patients (84%) either modality of revascularization was recommended.
13 However in the 40 patients (12%) where CABG was modality of choice, a heart team
14 discussion was performed only in 3 cases.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fractional flow reserve, the current gold standard for the functional assessment of lesion severity²¹, is recommended (class I, level of evidence A) to identify haemodynamically relevant coronary lesions in stable patients when evidence of ischaemia is not available or to assess the functional consequences of moderate coronary stenoses.⁶ According to the ACL, the proportion of patients without documented ischemia or borderline coronary stenoses who had a FFR guided PCI was 25% although the absolute numbers were small (7 FFR in 28 patients). While recent data suggest that FFR use is increasing, these data indicate another gap in use of a well-established technique to define physiological consequences of a coronary stenosis thus optimizing appropriate indication for revascularization.

Finally, we observed that prescription of guideline-directed medical therapy before PCI was suboptimal with just 23% of patients on “optimal medical therapy” and a high prescription only for antiplatelet therapy before PCI (>90%). This gap may

1
2
3 have multiple reasons including resource availability, patient's compliance, and
4
5 physician preference but should be an important, and easily modifiable target, for any
6
7 quality improvement initiative. By quality we intend the degree of match between
8
9 health care services and the needs they are intended to meet.²² APACHE was
10
11 designed to first quantify this match, inform the design of future investigations on this
12
13 topic (including a planned larger initiative in Italy extended to the whole country
14
15 designed to develop, implement, and adhere to shared heart team protocols), and
16
17 promote a continuous review of practice that may, in turn, inform a more effective,
18
19 efficient, and equitable resources allocation, and ultimately, better outcomes for
20
21 patients.
22
23
24
25
26
27

28 **Conclusions**

29 Use of heart teams approaches and adherence to guideline recommendation on
30
31 coronary revascularization in a real world setting is limited. The APACHE study
32
33 identifies substantial opportunities to improve the care of patients undergoing PCI.
34
35
36
37
38
39
40

41 **Acknowledgments**

42
43 We thank all investigators and patients who participated in this study to pioneer
44
45 advancements in clinical care.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Chan PS, Rao SV, Bhatt DL, Rumsfeld JS, Gurm HS, Nallamothu BK, Cavender MA, Kennedy KF, Spertus JA. Patient and hospital characteristics associated with inappropriate percutaneous coronary interventions. *J Am Coll Cardiol* 2013;62(24):2274-81.
2. Baig SS, Altman DG, Taggart DP. Major geographical variations in elective coronary revascularization by stents or surgery in England. *Eur J Cardiothorac Surg* 2014.
3. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/ SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol* 2012;59(9): 857-81.
4. Desai NR, Bradley SM, Parzynski CS, Nallamothu BK, Chan PS, Spertus JA, Patel MR, Ader J, Soufer A, Krumholz HM, Curtis JP. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. *JAMA* 2015;314(19):2045-53.
5. Maier W, Enderlin MF, Bonzel T, Danchin N, Heyndrickx G, Mühlberger V, Neuhaus KL, Piscione F, Reifart N, Antoni J, Ogurol Y, Wischnewsky MB, Meier B. Audit and quality control in angioplasty in Europe: procedural results of the AQUA Study 1997: assessment of 250 randomly selected coronary interventions performed in 25 centres of five European countries. AQUA Study Group, Nucleus Clinical Issues, Working Group Coronary Circulation, of the European Society of Cardiology. *Eur Heart J* 1999;20(17):1261-70.
6. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;35(37):2541-619.
7. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C,

- 1
2
3 Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James
4 SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli
5 MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis
6 A, Wijns W, Windecker S, Yildirim A, Zamorano JL. 2013 ESC guidelines on
7 the management of stable coronary artery disease: the Task Force on the
8 management of stable coronary artery disease of the European Society of
9 Cardiology. *Eur Heart J* 2013 Oct;34(38):2949-3003.
- 10
11 8. Bonzel T, Schächinger V2, Dörge H3. Description of a Heart Team
12 approach to coronary revascularization and its beneficial long-term effect
13 on clinical events after PCI. *Clin Res Cardiol*. 2016;105(5):388-400.
- 14 9. Nallamothu BK, Tommaso CL, Anderson HV, Anderson JL, Cleveland JC Jr,
15 Dudley RA, Duffy PL, Faxon DP, Gurm HS, Hamilton LA, Jensen NC,
16 Josephson RA, Malenka DJ, Maniu CV, McCabe KW, Mortimer JD, Patel
17 MR, Persell SD, Rumsfeld JS, Shunk KA, Smith SC Jr, Stanko SJ, Watts B.
18 ACC/AHA/SCAI/AMA-Convended PCPI/NCQA 2013 performance measures
19 for adults undergoing percutaneous coronary intervention: a report of the
20 American College of Cardiology/American Heart Association Task Force on
21 Performance Measures, the Society for Cardiovascular Angiography and
22 Interventions, the American Medical Association-Convended Physician
23 Consortium for Performance Improvement, and the National Committee for
24 Quality Assurance. *J Am Coll Cardiol* 2014;63(7):722-45.
- 25
26 10. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo
27 A, Kappetein AP, Colombo A, Holmes DR Jr, Mack M, Feldman T, Morice
28 MC, Stähle E, Onuma Y, Morel MA, Garcia-Garcia HM, van Es GA,
29 Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics
30 to guide decision making between coronary artery bypass surgery and
31 percutaneous coronary intervention for individual patients: development and
32 validation of SYNTAX score II. *Lancet* 2013;381(9867):639-50.
- 33
34 11. Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB,
35 Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED,
36 Edwards FH, Anderson RP; Society of Thoracic Surgeons Quality
37 Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac
38 surgery risk models: part 1--coronary artery bypass grafting surgery. *Ann*
39 *Thorac Surg* 2009;88(1 Suppl):S2-22.
- 40
41 12. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR,
42 Lockowandt U. EuroSCORE II. *Eur J Cardiothorac Surg* 2012;41(4):734-44;
43 discussion 744-5.
- 44
45 13. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss
46 V, Manoharan G, Engström T, Oldroyd KG, Ver Lee PN, MacCarthy PA,
47 Fearon WF; FAME Study Investigators. Fractional flow reserve versus
48 angiography for guiding percutaneous coronary intervention. *N Engl J Med*.
49 2009 Jan 15;360(3):213-24.
- 50
51 14. Hulley SB, Cummings SR, Browner WS, Grady D, Newman TB. Designing
52 clinical research : an epidemiologic approach. 4th ed. Philadelphia, PA:
53 Lippincott Williams & Wilkins; 2013. Appendix 6E, page 81.
- 54
55 15. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA; American
56 College of Cardiology Foundation Appropriateness Criteria Task Force.;
57 Society for Cardiovascular Angiography and Interventions.; Society of
58 Thoracic Surgeons.; American Association for Thoracic Surgery.; American
59 Heart Association, and the American Society of Nuclear Cardiology Endorsed
60

- 1
2
3 by the American Society of Echocardiography.; Heart Failure Society of
4 America.; Society of Cardiovascular Computed Tomography.
5 ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for
6 Coronary Revascularization: a report by the American College of Cardiology
7 Foundation Appropriateness Criteria Task Force, Society for Cardiovascular
8 Angiography and Interventions, Society of Thoracic Surgeons, American
9 Association for Thoracic Surgery, American Heart Association, and the
10 American Society of Nuclear Cardiology Endorsed by the American Society
11 of Echocardiography, the Heart Failure Society of America, and the Society of
12 Cardiovascular Computed Tomography. *J Am Coll Cardiol*. 2009 Feb
13 10;53(6):530-53
14
15 16. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B,
16 Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff
17 MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS,
18 Lee KL; PROMISE Investigators. Outcomes of anatomical versus functional
19 testing for coronary artery disease. *N Engl J Med*. 2015 Apr 2;372(14):1291-
20 300.
21
22 17. Lin GA, Dudley RA, Lucas FL, Malenka DJ, Vittinghoff E, Redberg RF.
23 Frequency of stress testing to document ischemia prior to elective
24 percutaneous coronary intervention. *JAMA* 2008;300(15):1765-73.
25
26 18. Lin GA, Lucas FL, Malenka DJ, Skinner J, Redberg RF. Mortality in
27 Medicare patients undergoing elective percutaneous coronary intervention
28 with or without antecedent stress testing. *Circ Cardiovasc Qual Outcomes*.
29 2013 May 1;6(3):309-14.
30
31 19. Garg S, Girasis C, Sarno G, Goedhart D, Morel MA, Garcia-Garcia HM,
32 Bressers M, van Es GA, Serruys PW; SYNTAX trial investigators. The
33 SYNTAX score revisited: a reassessment of the SYNTAX score
34 reproducibility. *Catheter Cardiovasc Interv*. 2010 May 1;75(6):946-52.
35
36 20. Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M, Kappetein AP,
37 Van Dyck N, Mack M, Holmes D, Feldman T, Morice MC, Colombo A, Bass
38 E, Leadley K, Dawkins KD, van Es GA, Morel MA, Mohr FW. Assessment of
39 the SYNTAX score in the syntax study. *EuroIntervention*. 2009;5(1):50-56.
40
41 21. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek
42 JKJJ, Koolen JJ. Measurement of fractional flow reserve to assess the
43 functional severity of coronary-artery stenoses. *N Engl J Med*
44 1996;334(26):1703-1708.
45
46 22. Berwick DM. Avoiding overuse-the next quality frontier. *Lancet* 2017; S0140-
47 6736(16)32570-3.
48
49
50
51
52
53
54
55
56
57
58
59
60

Text Tables

Table 1. Baseline characteristics, cardiovascular risk factors, and history stratified by clinical indication.

	Stable CAD (n=352)	NSTEACS (n=88)	Overall (n=440)
Age (years)	69.3 (62.9-75.1)	71 (63.4-77.4)	69.6 (63-75.8)
Females <i>n</i> (%)	71 (20)	27 (31)	98 (22)
BMI (kg/m ²)	26.2 (24.2-28.9)	27 (24.6-30)	26.3 (24.2-29.3)
Creatinine (mg/dl)	0.9 (0.79,1.08)	0.97 (0.85, 1.18)	0.91 (0.8, 1.10)
SYNTAX score	12 (8-20)	15 (8-20)	13 (8-20)
CV Risk Factors			
Diabetes <i>n</i> (%)	173 (49)	43 (49)	216 (49)
Hypertension <i>n</i> (%)	262 (75)	71 (78)	333 (75)
Dyslipidemia <i>n</i> (%)	190 (54)	48 (55)	238 (54)
Active smoker <i>n</i> (%)	53 (15)	16 (18)	69 (16)
Prior Smoker <i>n</i> (%)	85 (24)	13 (15)	98 (22)
History of premature CAD <i>n</i> (%)	99 (28)	19 (22)	118 (27)
History			
Prior Angina <i>n</i> (%)	250 (71)	52 (59)	302 (69)
Prior MI <i>n</i> (%)	95 (27)	20 (23)	115 (26)
Prior PCI <i>n</i> (%)	148 (42)	28 (32)	176 (40)
Renal Insufficiency <i>n</i> (%)	38 (11)	20 (23)	58 (13)
Heart Failure <i>n</i> (%)	14 (4)	2 (2)	16 (4)
LVSD <i>n</i> (%)	23 (7)	8 (9)	31 (7)
COPD <i>n</i> (%)	26 (7)	8 (9)	34 (8)
Stroke <i>n</i> (%)	18 (5)	5 (6)	23 (5)
PAD <i>n</i> (%)	55 (16)	10 (11)	65 (15)

Legend. BMI, Body mass index; SYNTAX: synergy between percutaneous coronary intervention with TAXUS and cardiac surgery; SCAD: coronary artery disease; NSTEMACS: non-ST elevation acute coronary syndrome; MI: myocardial infarction; PCI: percutaneous coronary intervention; LVSD: left ventricular systolic dysfunction defined as ejection fraction of 0.40 or less; COPD: Chronic obstructive pulmonary disease; PAD: peripheral artery disease.

Table 2. Characterization of the indication for PCI in patients with stable CAD (n=352).

Parameter	Value
Pre-Test Probability of CAD (%) [#]	69 (54-84)
Low (<15%) n (%)	0 (0)
Intermediate (15-85%) n (%)	222 (78)
High (>85%) n (%)	61 (22)
<i>Ad hoc</i> PCI n (%)	307 (87)
Any functional test of ischemia performed n (%) [*]	217 (62)
Exercise electrocardiography n	153
SPECT n	46
Stress echocardiography n	31
Stress cardiac magnetic resonance imaging n	3
Coronary computed tomographic angiography n (%)	27 (8)
No functional or anatomical testing n (%)	125 (35%)
AUC _{CORE} mappable	318 (90)
Appropriate n (%)	102 (32)
Uncertain n (%)	163 (51)
Inappropriate n (%)	52 (16)
AUC _{SITE} mappable	320 (91)
Appropriate n (%)	100 (31)
Uncertain n (%)	163 (51)
Inappropriate n (%)	57 (18)

[#]: Calculated according to (5) only in patients with unknown coronary anatomy (n=285): defined as a history of invasive coronary angiography or coronary computed tomography angiography in the year preceding the index PCI. ^{*}: Some patients (n=15) underwent more than 1 functional test before PCI 1 patient received 3 tests; SPECT: Single-Photon Emission Computed Tomography.

Author contributions:

Sergio Leonardi and Stefano De Servi: Study design, manuscript drafting, statistical analysis and critical revision.

Marcello Marino and Gabriele Crimi: angiographic core lab analysis, critical revision.

Florinda Maiorana, Diego Rizzotti: Data management, statistical analysis and critical revision

Corrado Lettieri, Luca Bettari, Marco Zuccari, Paolo Sganzerla, Simone Tresoldi, Marianna Adamo, Sergio Ghiringhelli, Carlo Sponzilli, Giampaolo Pasquetto, Andrea Pavei, Luigi Pedon, Luciano Bassan, Mario Bollati, Paola Camisasca, Daniela Trabattoni, Marta Brancati, Arnaldo Poli, Claudio Panciroli: critical Revision

Maddalena Lettino, Giuseppe Tarelli, Giuseppe Tarantini, Leonardo de Luca, Ferdinando Varbella: Central Heart Team and critical revision

Giuseppe Musumeci: Study design and critical revision

Competing interests

ICJME forms are available for all authors.


Dr Leonardi reports honoraria for advisory boards from AstraZeneca, Daiichi Sankyo, and The Medicines Company during the conduct of the study outside the submitted work; Dr. De Luca reports personal fees from Astra Zeneca, personal fees from Bayer, personal fees from Boehringer-Ingelheim, personal fees from

1
2
3 Eli Lilly and Daiichi Sankyo, personal fees from Menarini , personal fees from The
4 Medicines Company, outside the submitted work. Dr. De Servi reports personal
5 fees from Pfizer, personal fees from AstraZeneca, personal fees from Daichi-
6 sankyo, personal fees from Correvio, outside the submitted work. The other
7 authors report nothing to disclose. All authors have read and understood BMJ
8 policy on declaration of interests and have no other relevant interests to declare
9 in addition to these.
10

11 12 13 **Data Sharing Statement**


14 No additional unpublished data for this study will be available.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Histogram of Appropriate Use Score according to site-reported coronary anatomy (AUSSITE) in patients with and without diabetes.

53x42mm (300 x 300 DPI)




Error bars of AUSsite (left) and AUScore (right) by participating site. The dotted line indicates the median AUS site level (5.8).

106x42mm (300 x 300 DPI)

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Boxplot of AUScore in patients who underwent and who did not undergo local heart team discussion, stratified by diabetes status.

53x42mm (300 x 300 DPI)

View Only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	Indicate the study's design with a commonly used term in the title or the abstract (Title Page)
		(a)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found (Abstract Page 2)
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported (Introduction, page 4)
Objectives	3	State specific objectives, including any prespecified hypotheses (Objective, abstract)
Methods		
Study design	4	Present key elements of study design early in the paper (Study Design, page 5)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection (Methods, page 5 and Results, page 11)
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants (Methods, page 5, Patient Selection Section)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable (Methods, page 5)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group (Methods, page 5 Data Collection Section)
Bias	9	Describe any efforts to address potential sources of bias (Methods, page 5)
Study size	10	Explain how the study size was arrived at (Sample Size Consideration, page 10)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why (Statistical Section for all below, page 10)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (Results, page 11) (b) Give reasons for non-participation at each stage (NA) (c) Consider use of a flow diagram (NA)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (Results, page 11) (b) Indicate number of participants with missing data for each variable of interest (Results, page 11)
Outcome data	15*	Report numbers of outcome events or summary measures (Results, page 11)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were

		adjusted for and why they were included (Results, page 11)
		(b) Report category boundaries when continuous variables were categorized (Results, page 11)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period (Results, page 11)
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses (Results, page 11)
Discussion		
Key results	18	Summarise key results with reference to study objectives (Discussion, page 15)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias (Discussion, page 15)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence (Discussion, page 15)
Generalisability	21	Discuss the generalisability (external validity) of the study results (Discussion, page 15)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based (Funding Statement, page 10)

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

APpropriateness of percutaneous Coronary interventions in patients with ischemic HEart disease in Italy: The APACHE Pilot study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016909.R2
Article Type:	Research
Date Submitted by the Author:	26-Jul-2017
Complete List of Authors:	<p>Leonardi, Sergio; Fondazione IRCCS Policlinico San Matteo, Marino, Marcello; Aziende Socio Sanitarie Territoriale di Crema Crimi , Gabriel ; Fondazione IRCCS Policlinico San Matteo, Maiorana, Florinda; Fondazione IRCCS Policlinico San Matteo Rizzotti, Diego; Fondazione IRCCS Policlinico San Matteo Lettieri, Corrado; Azienda Socio Sanitaria Territoriale di Mantova Bettari, Luca; Azienda Socio Sanitaria Territoriale di Cremona Zuccari, Marco</p> <p>Sganzerla, Paolo; Agenzia di Tutela della Salute di Bergamo Ovest Tresoldi, Simone ; Azienda Ospedaliera di Desio e Vimercate Adamo, Marianna; Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</p> <p>Ghiringhelli, Sergio; Ospedale di Circolo e Fondazione Macchi Sponzilli, Carlo; Ospedale San Paolo</p> <p>Pasquetto, Giampaolo; Presidio Ospedaliero di Monselice Pavei, Andrea; Presidio di Conegliano</p> <p>Pedon, Luigi; Presidio Ospedaliero di Cittadella Bassan, Luciano; Azienda ULSS 4 Alto Vicentino</p> <p>Bollati, Mario; IRCCS Policlinico San Donato Camisasca, Paola; Azienda Ospedaliera San Gerardo</p> <p>Trabattoni, Daniela; Centro Cardiologico Monzino</p> <p>Brancati, Marta; Fondazione Poliambulanza Istituto Ospedaliero Poli, Arnaldo; Aziende Socio Sanitarie Territoriale Ovest Milanese Panciroli, Claudio</p> <p>Lettino, Maddalena; Istituto Clinico Humanitas</p> <p>Tarelli, Giuseppe; Istituto Clinico Humanitas</p> <p>Tarantini, Giuseppe; Azienda Ospedaliera di Padova</p> <p>De Luca, Leonardo; Ospedale di Tivoli</p> <p>Varbella, Ferdinando; 1Cardiology Unit, Ospedale degli Infermi, Musumeci, Giuseppe; Azienda Ospedaliera S Croce e Carle Cuneo</p> <p>De Servi, Stefano; IRCCS Sesto San Giovanni</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Health services research
Keywords:	Coronary heart disease < CARDIOLOGY, Percutaneous Coronary Intervention, Multidisciplinary Decision Making

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For peer review only

Appropriateness of percutaneous Coronary interventions in patients with ischemic HEart disease in Italy: The APACHE Pilot study

Sergio Leonardi, MD, MHS, FESC¹ Marcello Marino, MD² Gabriele Crimi, MD¹
Florinda Maiorana, MSc,¹ Diego Rizzotti, MSc¹ Corrado Lettieri, MD³ Luca Bettari,
MD⁴ Marco Zuccari, MD⁵ Paolo Sganzerla, MD⁶ Simone Tresoldi, MD⁷ Marianna
Adamo, MD⁸ Sergio Ghiringhelli, MD⁹ Carlo Sponzilli, MD¹⁰ Giampaolo Pasquetto,
MD¹¹ Andrea Pavei, MD¹² Luigi Pedon, MD¹³ Luciano Bassan, MD¹⁴ Mario Bollati,
MD¹⁵ Paola Camisasca, MD¹⁶ Daniela Trabattoni, MD¹⁷ Marta Brancati, MD¹⁸ Arnaldo
Poli, MD¹⁹ Claudio Panciroli, MD²⁰ Maddalena Lettino, MD²¹ Giuseppe Tarelli²¹, MD
Giuseppe Tarantini, MD²² Leonardo De Luca, MD²³ Ferdinando Varbella, MD²⁴,
Giuseppe Musumeci, MD²⁵ and Stefano De Servi, MD, FESC²⁶.

- 1: Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 2: Ospedale Maggiore di Crema, Crema, Italy
- 3: ASST Mantova – Ospedale Carlo Poma, Mantova, Italy
- 4: ASST Cremona – Ospedale di Cremona, Cremona, Italy
- 5: Ospedale Fornaroli di Magenta, Magenta, Italy
- 6: ASST Bergamo ovest – Ospedale di Treviglio, Italy
- 7: Azienda Ospedaliera di Desio e Vimercate, Vimercate, Italy
- 8: Spedali Civili di Brescia, Brescia, Italy
- 9: Ospedale di Circolo Fondazione Macchi, Varese, Italy
- 10: Ospedale San Paolo, Milano, Italy
- 11: Ospedali Riuniti Padova Sud Madre Teresa di Calcutta, Monselice, Italy
- 12: Presidio Ospedaliero di Conegliano, Conegliano, Italy
- 13: Presidio Ospedaliero di Cittadella, Cittadella, Italy
- 14: ULSS 4 Alto Vicentino, Thiene, Italy
- 15: IRCCS Policlinico San Donato, San Donato Milanese, Italy
- 16: Ospedale San Gerardo, Monza, Italy
- 17: Centro Cardiologico Monzino, Milano, Italy
- 18: Fondazione Poliambulanza, Brescia, Italy
- 19: ASST Ovest Milanese, Legnano, Italy
- 20: ASST di Lodi, Lodi, Italy
- 21: Humanitas Research Hospital, Rozzano (MI), Italy
- 22: Ospedale di Padova, Padova, Italy
- 23: Ospedale San Giovanni Evangelista, Tivoli (Rome), Italy
- 24: Ospedale degli Infermi, Rivoli, Italy
- 25: ASST – Papa Giovanni XXIII- Bergamo, Italy
- 26: IRCCS MultiMedica, Milano, Italy

Word Count: 4456

Address for correspondence

Sergio Leonardi, MD, MHS, FESC
Fondazione IRCCS Policlinico S. Matteo
Viale Golgi 19
27100
Pavia, Italy
S.Leonardi@smatteo.pv.it

Abstract *Word count: 305*

Objectives: To first explore in Italy appropriateness of indication, adherence to guideline recommendations, and mode of selection for coronary revascularization.

Design: Retrospective, pilot study.

Setting: Twenty-two percutaneous coronary intervention (PCI)-performing hospitals (20 patients/site), 13 (59%) with on-site cardiac surgery.

Participants: 440 patients who received PCI for stable coronary artery disease (CAD) or non-ST elevation acute coronary syndrome were independently selected in a 4:1 ratio with half diabetics.

Primary and Secondary Outcome Measures: Proportion of patients who received appropriate PCI using validated appropriate use scores (ie AUS ≥ 7). Also, in patients with stable CAD, we examined adherence to the following ESC recommendations: a) % of patients with complex coronary anatomy treated after heart-team discussion; b) % of fractional flow reserve-guided PCI for borderline stenoses in patients without documented ischemia; c) % of patients receiving guideline-directed medical therapy at the time of PCI as well as use of provocative test of ischemia according to pre-test probability (PTP) of CAD.

Results: Of the 401 mappable PCIs (91%), 38.7% (95%CI: 33.9-43.6) were classified as appropriate, 47.6% (95%CI: 42.7-52.6) as uncertain, and 13.7% (95%CI: 10.5-17.5%) as inappropriate. Median PTP in stable CAD patients without known coronary anatomy was 69% (78% intermediate PTP, 22% high PTP). Ischemia testing use was similar ($p=0.71$) in patients with intermediate ($n=140$, 63%) and with high PTP ($n=40$, 66%). In patients with stable CAD ($n=352$) guideline adherence to the 3 recommendations explored was: a) 11%; b) 25%; c) 23%. AUS was higher in patients

1
2
3 evaluated by the heart team as compared to patients who were not [7 (6,8) vs 5 (4,7);
4
5 P=0.001].
6

7 **Conclusions:** Use of heart-teams approaches and adherence to guideline
8
9 recommendations on coronary revascularization in a real world setting is limited. This
10
11 pilot study documents the feasibility of measuring appropriateness and guideline
12
13 adherence in clinical practice and identifies substantial opportunities for quality
14
15 improvement.
16
17

18 **Study Registration:** NCT02748603.
19
20
21
22
23
24

25 **Strengths and limitations of this study**

26

- 27
28 • APACHE is a first-in-class study in Italy designed to measure the degree of
29
30 appropriateness of indication, multi-disciplinary decision-making processes, and
31
32 implementation of key guideline recommendations in patients undergoing PCI.
- 33
34 • This study, that enrolled patients with stable CAD and diabetes, was intentionally
35
36 designed to focus on high-risk patients for inappropriate PCI. Therefore true
37
38 appropriateness of PCI may be underestimated. However, rather than an
39
40 epidemiological study, APACHE intention was to serve as first initiative
41
42 sponsored by a national medical society to measure care process and improve
43
44 quality.
- 45
46 • APACHE examined the appropriateness of PCI indication, not of coronary
47
48 angiography. Therefore we acknowledge as a limitation that we have no data to
49
50 inform appropriateness of surgical revascularization, nor indication to invasive
51
52 angiography.
53
54
55
56
57
58
59
60

Introduction

Percutaneous coronary intervention (PCI) has dramatically improved the prognosis of patients with coronary artery disease (CAD). Yet, many patients receive PCI whose clinical indication appears uncertain or inappropriate, especially in the non-acute setting.^{1,2} The development of appropriate use criteria by cardiovascular societies has provided the basis for a standardized approach to systematically assess the clinical appropriateness of PCI³ and has produced a reduction of the volume of non-acute PCI as well as an increase in the proportion of procedures classified as appropriate⁴ but these studies have been mostly performed in the US.

In Europe, data on appropriateness of indication and mode of selection for coronary revascularization strategies as well as the degree of implementation of guideline recommendations are limited.⁵ European Society of Cardiology (ESC) guidelines^{6,7} urge the implementation of a multidisciplinary decision-making approach – the heart team – to select the optimal mode of revascularization but data on the implementation of this process in patients with complex coronary artery disease (CAD), including those with stable CAD and diabetes, are scarce.⁸ Specifically the ESC^{6,7} recommend that 1) complex pathologies in stable patients, including lesions of the left main or proximal left anterior descending artery (LAD) and three-vessel disease, should in general not be treated *ad hoc*, but discussed by the heart team; 2) pressure derived fractional flow reserve (FFR) should be used to identify haemodynamically relevant coronary lesion(s) in stable patients when evidence of ischaemia is not available; and 3) patients with stable CAD must receive guideline-recommended medical treatment prior to revascularization.

We designed the APpropriAteness of percutaneous Coronary interventions in patients with ischemic HEart disease – APACHE Pilot study to first explore the degree of appropriateness of indication of PCI, multi-disciplinary decision-making

1
2
3 processes, and implementation of key guideline recommendations in patients
4
5 undergoing PCI in Italy.
6
7

8 9 **Methods**

10 11 **Study Design and Patient Selection**

12 APACHE was designed as a pilot initiative to assess appropriateness of PCI
13
14 indication and adherence to key guideline recommendations on coronary
15
16 revascularization in patients with predominantly stable CAD and diabetes, considered
17
18 to be at high risk for inappropriate indication and mode for coronary revascularization
19
20 (ie PCI treatment in patients with an indication for CABG). All PCI performing
21
22 hospitals of the Lombardia and Veneto region in Italy, serving a population of \approx
23
24 15.000.000 people, were invited to participate in the study. Twenty-two sites agreed
25
26 to participate, obtained regulatory approval, and were eventually included.
27
28

29
30 At each participating hospital, 20 patients were independently selected on-site
31
32 by the study team (see online appendix) among consecutive patients who were
33
34 admitted in the previous year for an elective procedure to treat stable CAD or urgently
35
36 for an episode of non-ST elevation acute coronary syndrome in a 4:1 ratio without site
37
38 personnel involvement in the selection of the cases identified to minimize selection
39
40 bias. The study population was also selected to preserve an overall 1:1 ratio on
41
42 diabetes status. If the number of patients selected was insufficient older cases were
43
44 evaluated for possible inclusion. Due to the low likelihood of receiving a *redo*
45
46 procedure as well as the inability to measure a SYNTAX score, patients with a history
47
48 of bypass surgery were excluded.
49
50
51
52

53 54 **Data Collection, Core Angiographic Assessment, and Central Heart Team**

55 Variables of interest were collected by the study team during dedicated visits
56
57 at participating hospitals via clinical chart abstraction. Sites were requested to provide
58
59
60

1
2
3 the complete clinical chart, including the coronary angiogram of the index PCI.
4
5 Source documentation was reviewed in full to abstract symptoms status (angina
6
7 class); cardiovascular risk factors and comorbidities; medical therapy at time of PCI;
8
9 site-reported indication for PCI; presence, results, and timing of any noninvasive
10
11 functional test, fractional flow reserve (FFR) or intracoronary imaging, if performed;
12
13 coronary anatomy and reported significance of angiographic stenoses for treated
14
15 lesion(s) on the catheterization report; and evidence for heart-team discussion
16
17 involving a cardiac surgeon. Finally, pretest probability (PTP) of significant coronary
18
19 artery disease was calculated in patients with stable CAD according to guideline
20
21 recommendations ⁷.
22
23
24

25 The Angiographic Core Laboratory (ACL) was composed by two independent
26
27 physicians with experience in interventional cardiology (MM, GC) who centrally and
28
29 independently reviewed coronary angiography for each patient to define 1) baseline
30
31 SYNTAX score 2) category of coronary anatomy (eg. one, two or three-vessel CAD
32
33 with or without proximal LAD involvement) ³ and 3) presence of “borderline”
34
35 angiographic stenoses (50% to 60%). For the SYNTAX score a disagreement was
36
37 arbitrarily considered to be present if there was a between score difference ≥ 10 or
38
39 both scores were not in the same tertile (0-22, 23-32, >32). In case of agreement an
40
41 average SYNTAX score was calculated. In case of disagreement between reviewers
42
43 the case was first resolved by consensus. If a consensus could not be reached (or if the
44
45 case was deemed particularly challenging) the conflict was resolved by the central
46
47 heart team. Anatomical category and presence of borderline coronary stenoses were
48
49 analyzed by a single reviewer (GC or MM).
50
51
52
53

54 The central heart team was represented by four members – two interventional
55
56 cardiologists (LDL, FV), one cardiac surgeon (GT), and one clinical cardiologist
57
58
59
60

(ML) – nominated by the Italian Society of Interventional Cardiology (SICI-GISE) among recognized experts in their respective specialty. The role of the central heart team was to review cases with unresolved conflicts by the ACL, cases considered complex or challenging by the study team or cases with incomplete or conflicting documentation. Assessments of the central heart team were performed by consensus.

Evaluation of Appropriateness of Indications for Coronary Revascularization

The comprehensive documentation of indications for PCI was formally examined based on the 2013 ACC/AHA/SCAI/AMA-PCPI/NCQA Percutaneous Coronary Intervention Measurement Set.⁹ This diagnostic measure was defined as the proportion of patients whose clinical documentation includes, at a minimum, the following elements:

1. Priority (acute coronary syndrome, elective, urgent, emergency/salvage); 2. Presence and severity of angina symptoms (eg, Canadian Cardiovascular Society classification system); 3. Use of antianginal medical therapies within 2 weeks before the procedure, if any; 4. Presence, results, and timing of noninvasive stress test, FFR, or intravascular ultrasound, if performed; and 5. Significance of angiographic stenosis on coronary angiography for treated lesion.

Appropriateness of indication of coronary revascularization was examined by assigning to each procedure an appropriate use score (AUS), with a score of 1 indicating a completely inappropriate procedure to a score of 9 indicating a completely appropriate one.³ Scores of 7 to 9 indicate that revascularization is considered generally appropriate and likely to improve patients' symptoms or survival. Scores of 1 to 3 considered generally inappropriate while scores of 4 to 6 indicate a clinical scenario for which the likelihood that coronary revascularization will improve health outcomes or symptoms is uncertain. This score was defined by

1
2
3 considering clinical presentation; severity of angina; extent of ischemia on
4
5 noninvasive testing; presence of other prognostic factors, such as congestive heart
6
7 failure or depressed left ventricular function; extent of medical therapy at the time of
8
9 PCI; and extent of anatomic coronary disease. If the scenario was not considered by
10
11 the consensus document,³ the procedure was considered non mappable.
12
13

14 To limit site operator-related bias, the study team calculated two scores for
15
16 each procedure:
17

- 18 1. AUS_{SITE}, based on site-reported extent of anatomic coronary disease;
- 19 2. AUS_{CORE}, based on ACL reported extent of anatomic coronary disease.
20
21
22

23 Evaluation of adherence to ESC Guidelines and Heart Team Processes

24 In patients with stable CAD we assessed adherence to three class I recommendations
25
26 according to ESC guidelines^{6,7}:
27
28

29 **Recommendation 1:** Proportion of patients with stable CAD and complex anatomy
30
31 [including lesions of the left main, proximal left anterior descending (LAD) and/or
32
33 three-vessel CAD] who were treated after local heart team discussion. This
34
35 recommendation was explored using both site-reported and ACL-reported coronary
36
37 anatomy. We also explored adherence to this recommendation by calculating the
38
39 proportion of patients with complex anatomy who received *ad hoc* PCI without
40
41 documented heart team discussion. To better define optimal mode of coronary
42
43 revascularization, the SYNTAX II score¹⁰ as well as the Society of Thoracic
44
45 Surgeons (STS)¹¹, and EuroScore II¹² were calculated.
46
47
48

49 **Recommendation 2:** Proportion of patients with stable CAD, no evidence of
50
51 ischemia, and borderline lesions according to the ACL in whom FFR was used to
52
53 identify haemodynamically relevant coronary lesion(s).
54
55

56 Specifically, this recommendation was explored as follows:
57
58
59
60

- 1
2
3 a) Proportion of patients with no functional test (ie test negative or not performed)
4 and at least one borderline stenosis according to ACL in whom pressure-derived
5 FFR was used;
6
7
8
9
10 b) Proportion of patients with no functional test or asymptomatic and at least one
11 borderline stenosis according to ACL in whom pressure derived FFR was used;
12
13
14 c) Proportion of patients with no functional test or asymptomatic and site-reported
15 multivessel CAD in whom pressure derived FFR was used.¹³
16
17

18 **Recommendation 3:** Proportion of patients with stable CAD who received guideline-
19 directed medical therapy prior to revascularization.⁷
20
21

22 Specifically:
23

- 24 a) Proportion of patients without known allergy or documented intolerance
25 taking low dose aspirin (75-150 mg daily) or clopidogrel;
26
27
28 b) Proportion of patients without known allergy or documented intolerance
29 receiving a statin;
30
31
32 c) Proportion of patients with heart failure, hypertension or diabetes treated with
33 an ACE-inhibitor or angiotensin receptor blocker;
34
35
36 d) Proportion of patients on optimal medical therapy defined as drugs for event
37 prevention (aspirin and/or clopidogrel; a statin; an ACE-I/ARB if heart failure,
38 hypertension or diabetes) plus at least one drug for angina relief if
39 symptomatic, such as beta-blockers, calcium channel blockers, long acting
40 nitrates, ivabradine, or ranolazine.
41
42
43
44
45
46
47
48

49 In patients with NSTEMI/ACS, we examined the proportion of PCI procedures
50 performed within 24 hours of admission in patients with a Global Registry of Acute
51 Coronary Events (GRACE) score > 140.
52
53
54
55
56
57
58
59
60

1
2
3 Finally we assessed, by structured investigators surveys, the presence of
4 written institutional protocols developed locally by the Heart Team in accordance
5 with current guidelines including specific anatomical criteria and clinical subsets that
6 may be (or should not be) treated *ad hoc* as well as the modalities and timing for
7 convocation of heart team meetings.
8
9
10
11
12

13 14 15 16 17 **Statistical Analysis and Sample Size Considerations**

18 Categorical data are presented as counts and proportion and continuous data as
19 median (25th, 75th percentile) and were analyzed, as appropriate, using chi-square (or
20 Fisher's exact) and Wilcoxon rank-sum test. We calculated 95% confidence intervals
21 for the proportion using the normal approximation to the binomial calculation. To
22 control for the effect of participating site as well as the presence of cardiac surgery
23 on-site on the primary outcome (AUS), we used ANOVA provided in the generalized
24 linear model procedure of SPSS version 20 including participating site and presence
25 of cardiac surgery on-site as co-factors for the key subgroup (factor) of interest (i.e.
26 patients evaluated by the heart team vs not").
27
28
29
30
31
32
33
34
35
36
37

38 Given the lack of prior studies to estimate appropriateness of coronary
39 revascularization in Italy, sample size estimation was challenging. The study was
40 powered on the primary subgroup of interest, patients with stable CAD, assuming an
41 appropriateness of 35% in this patient population based on prior reports.⁴ Using a
42 normal approximation to the binomial distribution for this proportion a population of
43 350 stable CAD patients was needed to obtain a 95% confidence interval between
44 30% and 40% for appropriateness.¹⁴ Analyses were performed using SPSS v 20 and
45 sample size was estimated using <http://www.sample-size.net/>. The study obtained
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 institutional review board approval by all participating hospitals and is registered on
4
5 ClinicalTrials.gov ID: NCT02748603.
6
7
8

9 10 **Sponsor and Funding**

11 The APACHE study was designed by the chair and principal investigator and
12
13 approved by the institutional review board at each participating center. The study was
14
15 sponsored by the Italian Society of Invasive Cardiology (SICI-GISE), a nonprofit
16
17 organization, and received unrestricted grant support from the Abbott Vascular and
18
19 Daiichi-Sankyo. The sponsor and funders had no role in the design of the study, the
20
21 collection, monitoring, analysis, and interpretation of the data, or the writing of the
22
23 report. The first draft of the manuscript was written by the first author. All the authors
24
25 vouch for the accuracy and completeness of the data and all analyses.
26
27
28

29 30 **Results**

31 Of the 22 hospitals included, 13 (59%) have onsite cardiac surgery and 4
32
33 (18%) are private hospitals. Overall, PCI procedures of 440 patients (performed
34
35 between January 2014 and May 2016) were included: 352 for patients with stable
36
37 CAD and 88 with NSTEMI [12 with unstable angina and 76 with non-ST elevation
38
39 myocardial infarction; median GRACE score 109 (89.5, 125.5), median Can Rapid
40
41 risk stratification of Unstable angina patients Suppress ADverse outcomes with Early
42
43 implementation of the ACC/AHA guidelines (CRUSADE) score 24 (16,40)]. A
44
45 SYNTAX score could be calculated in 422 patients (96%) with 87 disagreements
46
47 (21%) between ACL reviewers. Of these, 55 were resolved by consensus and 32 by
48
49 the central heart team. Clinical profile of the selected patients stratified by clinical
50
51 indication is showed in **Table 1**. By design, \approx half of the patients had diabetes
52
53 (n=216, 49.1%) with a high proportion of patients with dyslipidemia (54%), prior PCI
54
55 (40%) and history of angina (69%). **Table 2** presents data on indication and test
56
57
58
59
60

1
2
3 selection in patients with stable CAD. Median PTP of CAD in stable CAD patients
4 without known coronary anatomy was 69% (78% intermediate PTP, 22% high PTP,
5 no patient with low PTP). The use of provocative tests of ischemia was similar
6 (p=0.71) in patients with intermediate (n=140, 63%) and with high PTP (n=40, 66%).
7
8 Of the 88 patients with NSTEMI, a GRACE score > 140 was present in 11 (12%)
9 patients. Of these, 5 patients had PCI within 24 hours.
10
11

12
13
14
15
16
17 Two of the secondary outcomes listed on *ClinicalTrials.gov* ie 1) proportion
18 of patients receiving incomplete revascularization (i.e. residual SYNTAX > 8) and 2)
19 proportion of patients with nSTEMI who are stabilized (no recurrent ischemic
20 symptoms) who have multivessel disease and a high SYNTAX score (>22), without
21 documentation of Heart Team discussion in the medical records for nSTEMI-ACS were
22 not considered due to the limited reproducibility observed for the SYNTAX score and
23 the small number of subjects (n=3), respectively.
24
25
26
27
28
29
30
31

32 33 **Comprehensive Documentation and Appropriateness of Indications for** 34 **Coronary Revascularization** 35

36 A comprehensive documentation of PCI indication was present in 427 (97%) patients.
37
38 Most common reasons for unfulfilling this diagnostic measure were the lack of
39 documentation in the clinical chart of any non-invasive testing, both functional and
40 imaging (n=5) or missing information on therapy at admission (n=8).
41
42
43
44

45 An AUS_{SITE} could be calculated in 405 (92%) of patients while the remaining
46 35 patients did not have comprehensive documentation of indications for PCI or the
47 scenario was not applicable (ie non mappable AUC). The median AUS_{SITE} was 6 (5,7)
48 corresponding to 153 (37.8%, 95%CI: 33.1-43.5) of PCI classified as appropriate, 193
49 (47.7%, 95%CI: 42.8-52.5) as uncertain, and 59 (14.6%, 95%CI: 11.1-18) as
50 inappropriate AUC, similar in patients with a and without diabetes (**Figure 1 and**
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 2A**). AUS_{SITE} was higher in patients evaluated by the local heart team as
4 compared to patients who were not, both in unadjusted [7 (5,8) vs 5 (4,7); $p=0.003$]
5 and adjusted analysis (mean AUS_{SITE} 7.0, SD 1.8 vs 5.7 SD 1.9; $p=0.001$;
6 participating site and cardiac surgery on-site both non significant).
7
8
9
10

11 An AUS_{CORE} could be calculated in 401 patients (91%). Of these, 23 (6%)
12 required a review by the central heart team. Median AUS_{CORE} was 6 (5,7) with 155
13 (38.7%, 95%CI:33.9-43.4) of PCI classified as appropriate, 191 (47.6%,95%CI: 42.7-
14 52.5) as uncertain, and 55 (13.7%,95%CI:10.3-17.1) as inappropriate AUC. AUS_{CORE}
15 results by site and in key subgroups are reported in the **Figure 2B** and the
16 **Supplementary Figure respectively**. AUS_{CORE} was higher in patients with
17 NSTEMI as compared to patients with stable CAD with no significant difference
18 according to diabetic status or type of hospitals. AUS_{CORE} was higher in patients
19 evaluated by the local heart team as compared to patients who were not both in
20 unadjusted [7 (6,8) vs 5 (4,7); $p=0.001$] and adjusted analysis (mean AUS_{CORE} 7.1,
21 SD 1.5 vs 5.8 SD 1.9; $p=0.001$; participating site and cardiac surgery on-site both non
22 significant). (**Figure 3**).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Recommendation 1: Proportion of stable CAD patients with complex** 40 **pathologies who were treated after heart team discussion**

41 Of the 352 patients with stable CAD, 148 (42%) had a complex site-reported
42 coronary anatomy including significant lesions of the left main (n=16), proximal LAD
43 (n=73) and three-vessel disease (n=59). Of these, 17 (11%) underwent local heart
44 team discussion. Median operative mortality was low-to-intermediate as estimated by
45 both the Euroscore II [1.15 % (0.64, 2.05)] and the STS score [0.92% (0.45,1.81)].
46 Also, 118 of the 148 patients with complex site-reported coronary anatomy (80%)
47 received *ad hoc* PCI without evidence of discussion with the local heart team in the
48 clinical chart, with no difference in patients treated at hospitals with or without on-site
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 cardiac surgery ($p=0.74$). The proportion of patients with complex coronary lesions
4 according to the ACL was 46% ($n=164$). Of these, 20 (12%) underwent local heart
5 team discussion and 124 (75%) were treated *ad hoc* without evidence of heart team
6 discussion.
7
8
9

10 The median SYNTAX score in patients with stable CAD was 12 (8-20), with
11 83% of patients with a score < 23 , 13% between 23 and 32, and 4% above 32.
12
13

14 A SYNTAX II score could be calculated in 337 cases (96%). Of these, CABG
15 was the recommended option for 40 patients (12%), PCI the recommended option for
16 14 (4%), and either mode of revascularization was recommended in the remaining
17 283 cases (84%). Of the 40 patients where SYNTAX II score recommended CABG a
18 local heart team discussion was performed in 3 cases (7%). Finally, a total of 75
19 stable CAD patients (21%) with diabetes and multi-vessel CAD underwent *ad hoc*
20 PCI without local heart team discussion documented in the patient's chart.
21
22
23
24
25
26
27
28
29
30
31

32 **Recommendation 2: Proportion of stable CAD patients with no evidence of** 33 **ischemia where pressure derived fractional flow reserve (FFR) was used to** 34 **identify haemodynamically relevant coronary lesion(s).** 35 36

37 Of the 352 patients with stable CAD, 151 (43%) had no objective evidence of
38 ischemia (135 patients had no provocative test of ischemia, 8 had negative testing and
39 8 inconclusive testing), 36 (10%) were asymptomatic and 82 (23%) had multi-vessel
40 CAD according to the site. A pressure-derived FFR to guide PCI was used for 29
41 patients (8.2%) with stable CAD while intravascular ultrasound for 12 patients (3%).
42
43
44
45
46
47
48 No PCI were guided by coronary optical coherence tomography.
49

50 Of the 151 patients with no evidence of ischemia, the ACL identified 28
51 patients (18%) with at least one borderline coronary lesion treated with PCI with FFR
52 performed in 7 of these 28 cases (25%).
53
54
55
56
57
58
59
60

1
2
3 Of the 175 (50%) patients who had no objective evidence of ischemia or were
4 asymptomatic, 33 borderline lesions were identified by the ACL with FFR performed
5 in 10 cases. In the subgroup of 91 patients who also had site-reported multi-vessel
6 CAD, 13 borderline lesions were identified by the ACL, with FFR performed in 4
7 cases.
8
9

14 **Recommendation 3: Use of guideline-directed medical therapy at the time of** 15 **PCI in patients with stable CAD**

16
17
18 Of the 352 patients with stable CAD, 299 (85%) were treated with single
19 antiplatelet therapy at the time of angiography (292 low-dose aspirin and 7 with
20 clopidogrel) and 20 (6%) received dual antiplatelet therapy with aspirin and
21 clopidogrel (only 1 reported case of aspirin intolerance who successfully underwent
22 aspirin desensitization); 266 (76%) were on a statin (no reported case of statin
23 intolerance); 202 (57%) received an ACE-I or an angiotensin receptor blocker (no
24 reported case of allergy or intolerance). Among the subgroup of stable CAD patients
25 with hypertension, heart failure (or asymptomatic left ventricular ejection fraction of
26 40% or less), or diabetes (N=265; 75% of the overall stable CAD population), a
27 treatment with ACE-I or ARB was given to 176 patients (66%). Finally, a therapy
28 with an anti-anginal agent (beta-blocker, calcium channel blocker, nitrates,
29 ivabradine, or ranolazine) was administered to 237 patients overall and to 169 patients
30 of the 248 with symptoms of angina (68%). Overall a total of 100 patients (23%)
31 received guideline-directed medical therapy at time of PCI.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Adoption of institutional heart-team protocols**

52 Investigators from all participating centers (n=22) were interviewed and all
53 responded. A written institutional heart-team protocol was available in 5 (23%)
54 centers (1 with on-site cardiac surgery, 4 without on-site cardiac surgery) while in
55
56
57
58
59
60

1
2
3 other 5 centers (3 with on-site cardiac surgery) heart team meetings were being
4
5 scheduled on a regular basis (usually weekly). All other hospitals (n=12) did not have
6
7 either a heart team institutional protocol or regularly planned heart team meetings.
8
9

10 Discussion

11 In this pilot investigation we assessed appropriateness of indication of
12
13 coronary revascularization and adherence to key guideline recommendations in a real
14
15 world population with a high prevalence of stable CAD and diabetes as well as
16
17 multidisciplinary decision-making processes. We identified important gaps in
18
19 implementations of guideline recommendations and opportunities to improve the care
20
21 patients undergoing PCI.
22
23
24

25 Considerations on Appropriateness of Indication for Coronary 26 Revascularization

27 The proportion of appropriate indication for coronary revascularization was
28
29 39% in the overall population and 32% in patients with stable CAD with similar rates
30
31 observed using local vs ACL anatomical category. These proportions are similar to
32
33 what was observed in the US when AUC were first released in 2009.^{4,15} As expected,
34
35 appropriateness was higher in patients with NSTEMI as compared to patients with
36
37 stable CAD but similar according to diabetes status as well as in hospitals with and
38
39 without on-site cardiac surgery. Importantly both AUS_{SITE} and AUS_{CORE} were
40
41 significantly higher in patients who were evaluated by a heart team suggesting multi-
42
43 disciplinary decision-making is a surrogate of optimal revascularization choice.
44
45
46
47
48

49 In patients with stable CAD a functional testing strategy (used in 62% of
50
51 patients) was far more common than an anatomical-testing strategy with coronary
52
53 CTA (used only for 8% of patients), in agreement with the neutral findings of the
54
55 Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE)
56
57 trial.¹⁶ Notably, the use of functional testing was similar in patients with intermediate
58
59
60

1
2
3 and with high PTP of significant CAD suggesting that the determination of PTP,
4
5 considered the first major step in clinical decision making in this patient population,⁷
6
7 has limited influence in the real world to define a diagnostic strategy. Also, 33% of
8
9 stable CAD patients with unknown coronary anatomy had neither functional nor
10
11 anatomical testing before PCI and only 38% had maximal anti-ischemic medical
12
13 therapy before PCI, proportions that have contributed to the observed suboptimal
14
15 appropriateness and call for implementation of quality improvements initiatives.
16
17 Indeed, it has been observed that most (55.5%) of Medicare patients with stable CAD
18
19 do not have documentation of ischemia by noninvasive testing prior to elective PCI
20
21 and that pre-PCI stress testing was associated with lower mortality in patients
22
23 undergoing elective PCI.^{17,18} Overall these findings suggest a need to focus on PTP
24
25 assessment in decision-making, appropriate classification of risk by non-invasive
26
27 tests, and optimization of medical therapy before PCI.
28
29
30
31

32 Adherence to and Implementation of ESC Guidelines

33
34
35 To explore potential “specialty bias” – ie PCI treatment in patients with an
36
37 indication for CABG – we examined the proportion of patients with complex
38
39 coronary lesions, including significant disease of the left main, proximal LAD, and/or
40
41 three-vessel disease, who were treated *ad hoc* without evidence of heart team
42
43 discussion in the medical charts. We observed that only \approx one of ten eligible patients
44
45 underwent heart team discussion and 75 to 80% of patients with complex coronary
46
47 anatomy were treated *ad hoc*, with no significant differences in sites with and without
48
49 on-site cardiac surgery. To further explore this, we surveyed investigators to better
50
51 understand local decision-making processes. We observed that most sites did not have
52
53 a written institutional protocol and decision of heart team convocation was left at the
54
55 discretion of the interventional cardiologist on call. The high proportion of *ad hoc*
56
57
58
59
60

1
2
3 PCI in patients with complex disease together with the lack of structured local heart
4 teams identify a substantial opportunity to improve multidisciplinary decision making
5 processes and indicate the need for standardized institutional protocols, that 1) should
6 avoid the need for the systematic case-by-case review of all diagnostic angiograms
7 but guide the management of complex cases 2) define standards for heart team
8 composition and roles, and 3) generate consensus on practical ways to implement
9 them.

10
11
12 The SYNTAX score is also considered by the guidelines to inform choice on
13 optimal type of revascularization. This score, which relies on subjective assessment of
14 lesions using coronary angiography, is well known to have limited reproducibility.¹⁹
15 The highest kappa value observed in a study of the SYNTAX investigators to assess
16 intra-observer variability was 0.54, and only 0.36 for bifurcations¹⁹ and inter-
17 observer reproducibility was even lower.²⁰ We therefore decided to adopt a
18 conservative approach to define a disagreement between reviewers (arbitrarily defined
19 as a difference of at least 10 points or change of tertile) but still observed a
20 disagreement in 21% of patients. This variability suggests that for clinical decision-
21 making SYNTAX score should not be used in isolation but rather integrated with
22 clinical data. The SYNTAX II score was developed to address this need. By
23 implementing this score in the APACHE population, we observed that in the vast
24 majority of patients (84%) either modality of revascularization was recommended.
25 However in the 40 patients (12%) where CABG was modality of choice, a heart team
26 discussion was performed only in 3 cases.

27
28 Fractional flow reserve, the current gold standard for the functional
29 assessment of lesion severity²¹, is recommended (class I, level of evidence A) to
30 identify haemodynamically relevant coronary lesions in stable patients when evidence
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of ischaemia is not available or to assess the functional consequences of moderate
4 coronary stenoses.⁶ According to the ACL, the proportion of patients without
5 documented ischemia or borderline coronary stenoses who had a FFR guided PCI was
6 25% although the absolute numbers were small (7 FFR in 28 patients). While recent
7 data suggest that FFR use is increasing, these data indicate another gap in use of a
8 well-established technique to define physiological consequences of a coronary
9 stenosis thus optimizing appropriate indication for revascularization.
10
11
12
13
14
15
16
17

18 Finally, we observed that prescription of guideline-directed medical therapy
19 before PCI was suboptimal with just 23% of patients on “optimal medical therapy”
20 and a high prescription only for antiplatelet therapy before PCI (>90%). This gap may
21 have multiple reasons including resource availability, patient’s compliance, and
22 physician preference but should be an important, and easily modifiable target, for any
23 quality improvement initiative. By quality we intend the degree of match between
24 health care services and the needs they are intended to meet.²² APACHE was
25 designed to first quantify this match, inform the design of future investigations on this
26 topic (including a planned larger initiative in Italy extended to the whole country
27 designed to develop, implement, and adhere to shared heart team protocols), and
28 promote a continuous review of practice that may, in turn, inform a more effective,
29 efficient, and equitable resources allocation, and ultimately, better outcomes for
30 patients.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Conclusions

52 Use of heart teams approaches and adherence to guideline recommendation on
53 coronary revascularization in a real world setting is limited. The APACHE study
54 identifies substantial opportunities to improve the care of patients undergoing PCI.
55
56
57
58
59
60

Acknowledgments

We thank all investigators and patients who participated in this study to pioneer advancements in clinical care.

References

1. Chan PS, Rao SV, Bhatt DL, Rumsfeld JS, Gurm HS, Nallamothu BK, Cavender MA, Kennedy KF, Spertus JA. Patient and hospital characteristics associated with inappropriate percutaneous coronary interventions. *J Am Coll Cardiol* 2013;62(24):2274-81.
2. Baig SS, Altman DG, Taggart DP. Major geographical variations in elective coronary revascularization by stents or surgery in England. *Eur J Cardiothorac Surg* 2014.
3. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/ SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol* 2012;59(9): 857-81.
4. Desai NR, Bradley SM, Parzynski CS, Nallamothu BK, Chan PS, Spertus JA, Patel MR, Ader J, Soufer A, Krumholz HM, Curtis JP. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. *JAMA* 2015;314(19):2045-53.
5. Maier W, Enderlin MF, Bonzel T, Danchin N, Heyndrickx G, Mühlberger V, Neuhaus KL, Piscione F, Reifart N, Antoni J, Ogurol Y, Wischnowsky MB, Meier B. Audit and quality control in angioplasty in Europe: procedural results of the AQUA Study 1997: assessment of 250 randomly selected coronary interventions performed in 25 centres of five European countries. AQUA Study Group, Nucleus Clinical Issues, Working Group Coronary Circulation, of the European Society of Cardiology. *Eur Heart J* 1999;20(17):1261-70.
6. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on

- Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;35(37):2541-619.
7. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirim A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013 Oct;34(38):2949-3003.
 8. Bonzel T, Schächinger VZ, Dörge H3. Description of a Heart Team approach to coronary revascularization and its beneficial long-term effect on clinical events after PCI. *Clin Res Cardiol*. 2016;105(5):388-400.
 9. Nallamothu BK, Tommaso CL, Anderson HV, Anderson JL, Cleveland JC Jr, Dudley RA, Duffy PL, Faxon DP, Gurm HS, Hamilton LA, Jensen NC, Josephson RA, Malenka DJ, Maniu CV, McCabe KW, Mortimer JD, Patel MR, Persell SD, Rumsfeld JS, Shunk KA, Smith SC Jr, Stanko SJ, Watts B. ACC/AHA/SCAI/AMA-Convended PCPI/NCQA 2013 performance measures for adults undergoing percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convended Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance. *J Am Coll Cardiol* 2014;63(7):722-45.
 10. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, Colombo A, Holmes DR Jr, Mack M, Feldman T, Morice MC, Stähle E, Onuma Y, Morel MA, Garcia-Garcia HM, van Es GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. *Lancet* 2013;381(9867):639-50.
 11. Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP; Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. *Ann Thorac Surg* 2009;88(1 Suppl):S2-22.

12. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockowandt U. EuroSCORE II. *Eur J Cardiothorac Surg* 2012;41(4):734-44; discussion 744-5.
13. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engström T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med*. 2009 Jan 15;360(3):213-24.
14. Hulley SB, Cummings SR, Browner WS, Grady D, Newman TB. *Designing clinical research : an epidemiologic approach*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. Appendix 6E, page 81.
15. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA; American College of Cardiology Foundation Appropriateness Criteria Task Force.; Society for Cardiovascular Angiography and Interventions.; Society of Thoracic Surgeons.; American Association for Thoracic Surgery.; American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography.; Heart Failure Society of America.; Society of Cardiovascular Computed Tomography. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol*. 2009 Feb 10;53(6):530-53
16. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS, Lee KL; PROMISE Investigators. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015 Apr 2;372(14):1291-300.
17. Lin GA, Dudley RA, Lucas FL, Malenka DJ, Vittinghoff E, Redberg RF. Frequency of stress testing to document ischemia prior to elective percutaneous coronary intervention. *JAMA* 2008;300(15):1765-73.
18. Lin GA, Lucas FL, Malenka DJ, Skinner J, Redberg RF. Mortality in Medicare patients undergoing elective percutaneous coronary intervention with or without antecedent stress testing. *Circ Cardiovasc Qual Outcomes*. 2013 May 1;6(3):309-14.
19. Garg S, Girasis C, Sarno G, Goedhart D, Morel MA, Garcia-Garcia HM, Bressers M, van Es GA, Serruys PW; SYNTAX trial investigators. The SYNTAX score revisited: a reassessment of the SYNTAX score reproducibility. *Catheter Cardiovasc Interv*. 2010 May 1;75(6):946-52.
20. Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M, Kappetein AP, Van Dyck N, Mack M, Holmes D, Feldman T, Morice MC, Colombo A, Bass E, Leadley K, Dawkins KD, van Es GA, Morel MA, Mohr FW. Assessment of the SYNTAX score in the syntax study. *EuroIntervention*. 2009;5(1):50-56.
21. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek JKJ, Koolen JJ. Measurement of fractional flow reserve to assess the

- functional severity of coronary-artery stenoses. *N Engl J Med* 1996;334(26):1703–1708.
22. Berwick DM. Avoiding overuse—the next quality frontier. *Lancet* 2017; S0140-6736(16)32570-3.

Text Tables

Table 1. Baseline characteristics, cardiovascular risk factors, and history stratified by clinical indication.

	Stable CAD (n=352)	NSTEACS (n=88)	Overall (n=440)
Age (years)	69.3 (62.9-75.1)	71 (63.4-77.4)	69.6 (63-75.8)
Females <i>n</i> (%)	71 (20)	27 (31)	98 (22)
BMI (kg/m ²)	26.2 (24.2-28.9)	27 (24.6-30)	26.3 (24.2-29.3)
Creatinine (mg/dl)	0.9 (0.79,1.08)	0.97 (0.85, 1.18)	0.91 (0.8, 1.10)
SYNTAX score	12 (8-20)	15 (8-20)	13 (8-20)
CV Risk Factors			
Diabetes <i>n</i> (%)	173 (49)	43 (49)	216 (49)
Hypertension <i>n</i> (%)	262 (75)	71 (78)	333 (75)
Dyslipidemia <i>n</i> (%)	190 (54)	48 (55)	238 (54)
Active smoker <i>n</i> (%)	53 (15)	16 (18)	69 (16)
Prior Smoker <i>n</i> (%)	85 (24)	13 (15)	98 (22)
History of premature CAD <i>n</i> (%)	99 (28)	19 (22)	118 (27)
History			
Prior Angina <i>n</i> (%)	250 (71)	52 (59)	302 (69)
Prior MI <i>n</i> (%)	95 (27)	20 (23)	115 (26)
Prior PCI <i>n</i> (%)	148 (42)	28 (32)	176 (40)
Renal Insufficiency <i>n</i> (%)	38 (11)	20 (23)	58 (13)
Heart Failure <i>n</i> (%)	14 (4)	2 (2)	16 (4)
LVSD <i>n</i> (%)	23 (7)	8 (9)	31 (7)
COPD <i>n</i> (%)	26 (7)	8 (9)	34 (8)
Stroke <i>n</i> (%)	18 (5)	5 (6)	23 (5)
PAD <i>n</i> (%)	55 (16)	10 (11)	65 (15)

Legend. BMI, Body mass index; SYNTAX: synergy between percutaneous coronary intervention with TAXUS and cardiac surgery; SCAD: coronary artery disease; NSTEMACS: non-ST elevation acute coronary syndrome; MI: myocardial infarction; PCI: percutaneous coronary intervention; LVSD: left ventricular systolic dysfunction defined as ejection fraction of 0.40 or less; COPD: Chronic obstructive pulmonary disease; PAD: peripheral artery disease.

Table 2. Characterization of the indication for PCI in patients with stable CAD (n=352).

Parameter	Value
Pre-Test Probability of CAD (%) [#]	69 (54-84)
Low (<15%) n (%)	0 (0)
Intermediate (15-85%) n (%)	222 (78)
High (>85%) n (%)	61 (22)
<i>Ad hoc</i> PCI n (%)	307 (87)
Any functional test of ischemia performed n (%) [*]	217 (62)
Exercise electrocardiography n	153
SPECT n	46
Stress echocardiography n	31
Stress cardiac magnetic resonance imaging n	3
Coronary computed tomographic angiography n (%)	27 (8)
No functional or anatomical testing n (%)	125 (35%)
AUC _{CORE} mappable	318 (90)
Appropriate n (%)	102 (32)
Uncertain n (%)	163 (51)
Inappropriate n (%)	52 (16)
AUC _{SITE} mappable	320 (91)
Appropriate n (%)	100 (31)
Uncertain n (%)	163 (51)
Inappropriate n (%)	57 (18)

[#]: Calculated according to (5) only in patients with unknown coronary anatomy (n=285): defined as a history of invasive coronary angiography or coronary computed tomography angiography in the year preceding the index PCI. ^{*}: Some patients (n=15) underwent more than 1 functional test before PCI 1 patient received 3 tests; SPECT: Single-Photon Emission Computed Tomography.

Author contributions:

Sergio Leonardi and Stefano De Servi: Study design, manuscript drafting, statistical analysis and critical revision.

Marcello Marino and Gabriele Crimi: angiographic core lab analysis, critical revision.

Florinda Maiorana, Diego Rizzotti: Data management, statistical analysis and critical revision

Corrado Lettieri, Luca Bettari, Marco Zuccari, Paolo Sganzerla, Simone Tresoldi, Marianna Adamo, Sergio Ghiringhelli, Carlo Sponzilli, Giampaolo Pasquetto,

1
2
3 Andrea Pavei, Luigi Pedon, Luciano Bassan, Mario Bollati, Paola Camisasca,
4 Daniela Trabattoni, Marta Brancati, Arnaldo Poli, Claudio Panciroli: critical
5 Revision

6 Maddalena Lettino, Giuseppe Tarelli, Giuseppe Tarantini, Leonardo de Luca,
7 Ferdinando Varbella: Central Heart Team and critical revision
8
9 Giuseppe Musumeci: Study design and critical revision

10 11 **Competing interests**


12 ICJME forms are available for all authors.

13 Dr Leonardi reports honoraria for advisory boards from AstraZeneca, Daiichi
14 Sankyo, and The Medicines Company during the conduct of the study outside the
15 submitted work; Dr. De Luca reports personal fees from Astra Zeneca, personal
16 fees from Bayer , personal fees from Boehringer-Ingelheim, personal fees from
17 Eli Lilly and Daiichi Sankyo, personal fees from Menarini , personal fees from The
18 Medicines Company, outside the submitted work. Dr. De Servi reports personal
19 fees from Pfizer, personal fees from AstraZeneca, personal fees from Daichi-
20 sankyo, personal fees from Correvio, outside the submitted work. The other
21 authors report nothing to disclose. All authors have read and understood BMJ
22 policy on declaration of interests and have no other relevant interests to declare
23 in addition to these.
24
25
26
27

28 **Data Sharing Statement**


29 No additional unpublished data for this study will be available.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Histogram of Appropriate Use Score according to site-reported coronary anatomy (AUSSITE) in patients with and without diabetes.

53x42mm (300 x 300 DPI)




Error bars of AUSsite (left) and AUScore (right) by participating site. The dotted line indicates the median AUS site level (5.8).

106x42mm (300 x 300 DPI)

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Boxplot of AUScore in patients who underwent and who did not undergo local heart team discussion, stratified by diabetes status.

53x42mm (300 x 300 DPI)

APPENDIX

Executive Committee and Medical Leadership

Stefano De Servi (study chair), Sergio Leonardi (principal investigator), Giuseppe Musumeci (GISE Lombardia President), Giuseppe Tarantini (GISE Veneto President).

Data management

Florinda Maiorana, Diego Rizzotti, Arianna Elia.

Central Heart Team

Maddalena Lettino, Giuseppe Tarelli, Ferdinando Varbella, Leonardo De Luca.

Angiographic Core Laboratory

Marcello Marino, Gabriele Crimi

Investigators

Maurizio Ferrario, *Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*; Corrado Lettieri, *ASST Mantova – Ospedale Carlo Poma, Mantova, Italy*; Maurizio D'urbano, *Marco Zuccari Ospedale Fornaroli di Magenta, Magenta, Italy*; Enrico Passamonti, *Luca Bettari, Sergio Signore, Ospedale di Cremona, Cremona, Italy*; Paolo Sganzerla, *Mauro Rondi, Ospedale di Treviglio e Caravaggio, Treviglio, Italy*; Planca Enrico, *Simone Tresoldi, Azienda Ospedaliera di Desio e Vimercate, Vimercate, Italy*; Federica Etori, *Marianna Adamo, Spedali Civili di Brescia, Brescia, Italy*; Sergio Ghiringhelli, *Ospedale di Circolo Fondazione Macchi, Varese, Italy*; Carlo Sponzilli, *Ospedale San Paolo, Milano, Italy*; Giuseppe Musumeci, *Federica Piazzoni, ASST – Papa Giovanni XXIII- Bergamo, Italy*; Giampaolo Pasquetto, *Michela Facchin, Ospedali Riuniti Padova Sud Madre Teresa di Calcutta, Monselice, Italy*; Andrea Pavei, *Gerlando Preti, Presidio Ospedaliero di Conegliano, Conegliano, Italy*; Luigi Pedon, *Presidio Ospedaliero di Cittadella, Cittadella, Italy*; Luciano Bassan, *ULSS 4 Alto Vicentino, Thiene, Italy*; Francesco Bedogni, *Mario Bollati, Luca Testa, Giovanni Bianchi, IRCCS Policlinico San Donato, San Donato Milanese, Italy*; Paola Camisasca, *Ospedale San Gerardo, Monza, Italy*; Daniela Trabattoni, *Centro Cardiologico Monzino, Milano, Italy*; Ornella Leonzi, *Marta Brancati, Fondazione Poliambulanza, Brescia, Italy*; Arnaldo Poli, *Katia Stefanin, ASST Ovest Milanese, Legnano, Italy*; Claudio Panciroli, *Emanuele Prina, ASST di Lodi, Lodi, Italy*; Paolo Pagnotta, *Daniela Cattani, IRCCS Humanitas, Rozzano (MI), Italy*; Giuseppe Tarantini, *Ervis Hiso, Ospedale Di Padova, Padova, Italy*.


Sites

1. Fondazione IRCCS Policlinico San Matteo, Pavia (Coordinating Site)
2. ASST Mantova – Ospedale Carlo Poma, Mantova
3. Ospedale Fornaroli di Magenta, Magenta
4. Ospedale di Cremona, Cremona
5. Ospedale di Treviglio e Caravaggio, Treviglio
6. Azienda Ospedaliera di Desio e Vimercate, Vimercate
7. Spedali Civili di Brescia, Brescia
8. Ospedale di Circolo Fondazione Macchi, Varese

9. Ospedale San Paolo, Milano
10. ASST – Papa Giovanni XXIII- Bergamo
11. Ospedali Riuniti Padova Sud Madre Teresa di Calcutta, Monselice
12. Presidio Ospedaliero di Conegliano, Conegliano
13. Presidio Ospedaliero di Cittadella, Cittadella
14. ULSS 4 Alto Vicentino, Thiene
15. IRCCS Policlinico San Donato, San Donato Milanese
16. Ospedale San Gerardo, Monza
17. Centro Cardiologico Monzino, Milano
18. Fondazione Poliambulanza, Brescia
19. ASST Ovest Milanese, Legnano
20. ASST di Lodi, Lodi
21. IRCCS Humanitas, Rozzano (MI)
22. Ospedale di Padova, Padova.

Supplementary Figure

Title: AUS_{SCORE} for pre-defined study subgroups.



Legend: Appropriate Use Score for pre-defined subgroups including type of hospital (private or public), presence of cardiac surgery on site, diabetic patients, and clinical presentation (stable CAD or NSTEACS).

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	Indicate the study's design with a commonly used term in the title or the abstract (Title Page)
		(a)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found (Abstract Page 2)
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported (Introduction, page 4)
Objectives	3	State specific objectives, including any prespecified hypotheses (Objective, abstract)
Methods		
Study design	4	Present key elements of study design early in the paper (Study Design, page 5)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection (Methods, page 5 and Results, page 11)
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants (Methods, page 5, Patient Selection Section)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable (Methods, page 5)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group (Methods, page 5 Data Collection Section)
Bias	9	Describe any efforts to address potential sources of bias (Methods, page 5)
Study size	10	Explain how the study size was arrived at (Sample Size Consideration, page 10)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why (Statistical Section for all below, page 10)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (Results, page 11) (b) Give reasons for non-participation at each stage (NA) (c) Consider use of a flow diagram (NA)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (Results, page 11) (b) Indicate number of participants with missing data for each variable of interest (Results, page 11)
Outcome data	15*	Report numbers of outcome events or summary measures (Results, page 11)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were

		adjusted for and why they were included (Results, page 11)
		(b) Report category boundaries when continuous variables were categorized (Results, page 11)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period (Results, page 11)
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses (Results, page 11)
Discussion		
Key results	18	Summarise key results with reference to study objectives (Discussion, page 15)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias (Discussion, page 15)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence (Discussion, page 15)
Generalisability	21	Discuss the generalisability (external validity) of the study results (Discussion, page 15)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based (Funding Statement, page 10)

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.